<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK333437" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK333437/" /><meta name="ncbi_pagename" content="Action Myoclonus – Renal Failure Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Action Myoclonus – Renal Failure Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Action Myoclonus – Renal Failure Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/12/17" /><meta name="citation_author" content="Dina Amrom" /><meta name="citation_author" content="Frederick Andermann" /><meta name="citation_author" content="Eva Andermann" /><meta name="citation_pmid" content="26677510" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK333437/" /><meta name="citation_keywords" content="AMRF Syndrome" /><meta name="citation_keywords" content="Lysosome membrane protein 2" /><meta name="citation_keywords" content="SCARB2" /><meta name="citation_keywords" content="Action Myoclonus - Renal Failure Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Action Myoclonus – Renal Failure Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Dina Amrom" /><meta name="DC.Contributor" content="Frederick Andermann" /><meta name="DC.Contributor" content="Eva Andermann" /><meta name="DC.Date" content="2015/12/17" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK333437/" /><meta name="description" content="Action myoclonus – renal failure (AMRF) syndrome typically comprises a continuum of two major (and ultimately fatal) manifestations: progressive myoclonic epilepsy (PME) and renal failure; however, in some instances, the kidneys are not involved. Neurologic manifestations can appear before, simultaneously, or after the renal manifestations. Disease manifestations are usually evident in the late teens or early twenties. In the rare instances in which renal manifestations precede neurologic findings, onset is usually in late childhood / early adolescence but can range to the fifth or sixth decade. Neurologic manifestations begin with tremor at rest (which is exacerbated by fine motor activities) and progress to involuntary, action-activated myoclonic jerks that involve bulbar, proximal, and distal limb muscles; involuntary spontaneous myoclonic jerks; and generalized clonic-tonic-clonic seizures. Sensorimotor peripheral neuropathy and sensorineural hearing loss can also be observed. Renal manifestations include proteinuria that can progress to nephrotic syndrome and end-stage renal disease." /><meta name="og:title" content="Action Myoclonus – Renal Failure Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Action myoclonus – renal failure (AMRF) syndrome typically comprises a continuum of two major (and ultimately fatal) manifestations: progressive myoclonic epilepsy (PME) and renal failure; however, in some instances, the kidneys are not involved. Neurologic manifestations can appear before, simultaneously, or after the renal manifestations. Disease manifestations are usually evident in the late teens or early twenties. In the rare instances in which renal manifestations precede neurologic findings, onset is usually in late childhood / early adolescence but can range to the fifth or sixth decade. Neurologic manifestations begin with tremor at rest (which is exacerbated by fine motor activities) and progress to involuntary, action-activated myoclonic jerks that involve bulbar, proximal, and distal limb muscles; involuntary spontaneous myoclonic jerks; and generalized clonic-tonic-clonic seizures. Sensorimotor peripheral neuropathy and sensorineural hearing loss can also be observed. Renal manifestations include proteinuria that can progress to nephrotic syndrome and end-stage renal disease." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK333437/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/amrf/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK333437/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C224EE04171F100000000019F008E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK333437_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK333437_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/npab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/aip/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK333437_"><span class="title" itemprop="name">Action Myoclonus &#x02013; Renal Failure Syndrome</span></h1><p class="contrib-group"><span itemprop="author">Dina Amrom</span>, MD, <span itemprop="author">Frederick Andermann</span>, MD, FRCP(C), and <span itemprop="author">Eva Andermann</span>, MDCM, PhD, FCCMG.</p><a data-jig="ncbitoggler" href="#__NBK333437_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK333437_ai__"><div class="contrib half_rhythm"><span itemprop="author">Dina Amrom</span>, MD<div class="affiliation small">Neurogenetics Unit<br />Montreal Neurological Hospital &#x00026; Institute<br />Department of Neurology &#x00026; Neurosurgery<br />McGill University<br />Montreal, Quebec, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.lligcm.liam@morma.anid" class="oemail">ac.lligcm.liam@morma.anid</a><span style="unicode-bidi: bidi-override; direction: ltr;">; </span><a href="mailto:dev@null" data-email="eb.ca.blu@morma.anid" class="oemail">eb.ca.blu@morma.anid</a><div></div></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Frederick Andermann</span>, MD, FRCP(C)<div class="affiliation small">Epilepsy Research Group<br />Montreal Neurological Hospital &#x00026; Institute<br />Departments of Neurology &#x00026; Neurosurgery and Pediatrics<br />McGill University<br />Montreal, Quebec, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.lligcm@nnamredna.kcirederf" class="oemail">ac.lligcm@nnamredna.kcirederf</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Eva Andermann</span>, MDCM, PhD, FCCMG<div class="affiliation small">Neurogenetics Unit and Epilepsy Research Group<br />Montreal Neurological Hospital &#x00026; Institute<br />Departments of Neurology &#x00026; Neurosurgery and Human Genetics<br />McGill University<br />Montreal, Quebec, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.lligcm@nnamredna.ave" class="oemail">ac.lligcm@nnamredna.ave</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 17, 2015</span>.</p><p><em>Estimated reading time: 32 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="amrf.Summary" itemprop="description"><h2 id="_amrf_Summary_">Summary</h2><div><h4 class="inline">Clinical description.</h4><p>Action myoclonus &#x02013; renal failure (AMRF) syndrome typically comprises a continuum of two major (and ultimately fatal) manifestations: progressive myoclonic epilepsy (PME) and renal failure; however, in some instances, the kidneys are not involved. Neurologic manifestations can appear before, simultaneously, or after the renal manifestations. Disease manifestations are usually evident in the late teens or early twenties. In the rare instances in which renal manifestations precede neurologic findings, onset is usually in late childhood / early adolescence but can range to the fifth or sixth decade. Neurologic manifestations begin with tremor at rest (which is exacerbated by fine motor activities) and progress to involuntary, action-activated myoclonic jerks that involve bulbar, proximal, and distal limb muscles; involuntary spontaneous myoclonic jerks; and generalized clonic-tonic-clonic seizures. Sensorimotor peripheral neuropathy and sensorineural hearing loss can also be observed. Renal manifestations include proteinuria that can progress to nephrotic syndrome and end-stage renal disease.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of AMRF syndrome is suspected in a previously healthy teenager or young adult with the characteristic neurologic and/or renal manifestations. The diagnosis is confirmed in individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants in <i>SCARB2.</i></p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Symptomatic pharmacologic and psychosocial support is the mainstay of care for the neurologic manifestations. Response to treatment is variable and may worsen over time, necessitating rehabilitative management. Renal insufficiency requires dialysis but response to treatment is poor, and renal transplantation is often necessary.</p><p><i>Prevention of secondary complications:</i> Standard measures for prevention of aspiration pneumonia and sudden unexpected death in epilepsy should be followed.</p><p><i>Surveillance:</i> Lifelong follow up should include regular monitoring of antiepileptic drug treatment and renal function (including urinary protein excretion, creatinine clearance, and estimated glomerular filtration rate) and periodic assessment of hearing and peripheral nerves<i>.</i></p><p><i>Agents/circumstances to avoid:</i> Diphenylhydantoin, carbamazepine, oxcarbazepine, and possibly lamotrigine increase myoclonus and should be avoided in any individual with PME.</p><p><i>Pregnancy management:</i> Because some antiepileptic drugs can lead to an increased risk of malformations, growth retardation, or neurodevelopmental disabilities in exposed fetuses, standard measures for prevention of fetopathy should be followed.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>AMRF syndrome is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk require prior identification of the <i>SCARB2</i> pathogenic variants in the family.</p></div></div><div id="amrf.Diagnosis"><h2 id="_amrf_Diagnosis_">Diagnosis</h2><div id="amrf.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Action myoclonus &#x02013; renal failure (AMRF) syndrome <b>should be suspected</b> in a previously healthy teenager or young adult with the following neurologic and renal manifestations [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.vadlamudi.2006.1310">Vadlamudi et al 2006</a>, <a class="bk_pop" href="#amrf.REF.andermann.2011">Andermann 2011</a>]:</p><p><b>Neurologic manifestations</b></p><ul><li class="half_rhythm"><div>A fine tremor of the fingers and hands, present at rest, exacerbated by fine motor activities such as writing and relieved by alcohol or propranolol, is commonly the first finding. The tremor can later involve the head, trunk, lower extremities, and sometimes tongue and voice. In the later stages of the disease, it becomes masked by striking myoclonic jerks.</div></li><li class="half_rhythm"><div>Involuntary, action-activated myoclonic jerks, also induced by attempted and executed speech, involve bulbar as well as proximal and distal limb muscles. The myoclonus is reflex-sensitive to touch on the distal extremities.</div></li><li class="half_rhythm"><div>Involuntary spontaneous myoclonic jerks of the face (particularly perioral) as well as synchronous and asynchronous jerks of the trunk and limbs also occur at rest.</div></li><li class="half_rhythm"><div>Generalized clonic-tonic-clonic seizures, diurnal and/or nocturnal, start with a generalized clonic phase with preserved consciousness and proceed to unconsciousness with tonic-clonic features and urinary incontinence.</div></li><li class="half_rhythm"><div>Other findings can include sensorimotor peripheral neuropathy (most often predominantly demyelinating or more rarely axonal) and sensorineural hearing loss (SNHL).</div></li></ul><p><b>Renal manifestations</b></p><ul><li class="half_rhythm"><div>Proteinuria, the first manifestation of renal disease, is initially mild and asymptomatic.</div></li><li class="half_rhythm"><div>Renal disease can progress to nephrotic syndrome and end-stage renal disease.</div></li><li class="half_rhythm"><div>In some families, renal manifestations (eventually requiring renal transplantation) appear first in late childhood or early teens and neurologic manifestations in the late twenties or early thirties [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>].</div></li><li class="half_rhythm"><div>Histologic changes include interstitial fibrosis, atrophy, focal sclerosing glomerulonephritis sometimes with features of collapsing glomerulopathy (a severe variant of glomerulosclerosis), or membranous nephropathy. No storage was observed [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.berkovic.2008.673">Berkovic et al 2008</a>].</div></li><li class="half_rhythm"><div>Note: Immunostaining can show IgM and complement present in the glomerular loops and in the mesangium [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>]. In one patient, a C1q nephropathy has been shown by immunohistochemistry [<a class="bk_pop" href="#amrf.REF.balreira.2008.2238">Balreira et al 2008</a>, <a class="bk_pop" href="#amrf.REF.chaves.2011.738">Chaves et al 2011</a>], indicating an immune complex-mediated glomerular disease. In this patient, extensive tubular abnormalities were also present, as well as granular material in cortical tubules. No Gaucher cells were observed.</div></li></ul><p>A classification that takes into account the age at disease onset and the clinical manifestations has been proposed (<a class="figpopup" href="/books/NBK333437/table/amrf.T.clinical_manifestations_of_amrf/?report=objectonly" target="object" rid-figpopup="figamrfTclinicalmanifestationsofamrf" rid-ob="figobamrfTclinicalmanifestationsofamrf">Table 2</a>).</p></div><div id="amrf.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of action myoclonus &#x02013; renal failure (AMRF) syndrome <b>is confirmed</b> in individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants in <i>SCARB2</i> [<a class="bk_pop" href="#amrf.REF.balreira.2008.2238">Balreira et al 2008</a>, <a class="bk_pop" href="#amrf.REF.berkovic.2008.673">Berkovic et al 2008</a>] (<a class="figpopup" href="/books/NBK333437/table/amrf.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figamrfTmoleculargenetictestingusedin" rid-ob="figobamrfTmoleculargenetictestingusedin">Table 1</a>).</p><p>Note: Molecular diagnosis performed early in the disease course may eliminate the need for numerous invasive neurologic and renal investigations.</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div><b>Persons of French-Canadian ancestry.</b> It is appropriate to start with targeted analysis of the two most common pathogenic variants in that population: c.862C&#x0003e;T [<a class="bk_pop" href="#amrf.REF.berkovic.2008.673">Berkovic et al 2008</a>] and c.1187+3insT [<a class="bk_pop" href="#amrf.REF.dibbens.2011.812">Dibbens et al 2011</a>]. If no or only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, it is appropriate to perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>SCARB2.</i></div></li><li class="half_rhythm"><div><b>Persons not of French-Canadian ancestry.</b> It is appropriate to begin with <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>SCARB2.</i> If only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, it is reasonable to perform <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> next. However, to date, no <i>SCARB2</i> deletion/duplication has been reported to the authors' knowledge.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> for progressive myoclonic epilepsy (PME) or epilepsy that includes <i>SCARB2</i> and other genes of interest (see <a href="#amrf.Differential_Diagnosis">Differential Diagnosis</a>) may also be used. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, mitochondrial sequencing, and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>SCARB2</i>) fails to confirm a diagnosis in an individual with features of action myoclonus &#x02013; renal failure syndrome. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene that results in a similar clinical presentation.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="amrf.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Action Myoclonus &#x02013; Renal Failure Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK333437/table/amrf.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__amrf.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SCARB2</i></td><td headers="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Estimated from <a href="/books/NBK333437/bin/amrf-table4.pdf">Table 4</a>: 97.5%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis of pathogenic variants</td><td headers="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 5</td></tr><tr><td headers="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_amrf.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="amrf.TF.1.1"><p class="no_margin">See <a href="/books/NBK333437/#amrf.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="amrf.TF.1.2"><p class="no_margin">See <a href="#amrf.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="amrf.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="amrf.TF.1.4"><p class="no_margin">About 20 pathogenic variants have been reported to date (see <a class="figpopup" href="/books/NBK333437/table/amrf.T.scarb2_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figamrfTscarb2pathogenicvariantsdiscus" rid-ob="figobamrfTscarb2pathogenicvariantsdiscus">Tables 3</a> and <a href="/books/NBK333437/bin/amrf-table4.pdf">4</a>). About 2.5% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are compound heterozygotes with an identified intragenic <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and an unidentified variant in the other.</p></div></dd><dt>5. </dt><dd><div id="amrf.TF.1.5"><p class="no_margin">Testing for the pathogenic variants <a class="figpopup" href="/books/NBK333437/table/amrf.T.scarb2_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figamrfTscarb2pathogenicvariantsdiscus" rid-ob="figobamrfTscarb2pathogenicvariantsdiscus">c.862C&#x0003e;T</a> (see also <a href="/books/NBK333437/bin/amrf-table4.pdf">Table 4</a>) (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7) and <a class="figpopup" href="/books/NBK333437/table/amrf.T.scarb2_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figamrfTscarb2pathogenicvariantsdiscus" rid-ob="figobamrfTscarb2pathogenicvariantsdiscus">c.1187+3insT</a> (see also <a href="/books/NBK333437/bin/amrf-table4.pdf">Table 4</a>) (<a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 9) in persons of French-Canadian origin. In this population, the vast majority of probands are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for c.862C&#x0003e;T, whereas a small proportion are compound heterozygotes for both pathogenic variants [<a class="bk_pop" href="#amrf.REF.dibbens.2011.812">Dibbens et al 2011</a>].</p></div></dd><dt>6. </dt><dd><div id="amrf.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions and duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div><div id="amrf.Clinical_Characteristics"><h2 id="_amrf_Clinical_Characteristics_">Clinical Characteristics</h2><div id="amrf.Clinical_Description"><h3>Clinical Description</h3><p>Action myoclonus &#x02013; renal failure (AMRF) syndrome typically comprises a continuum of two major (and ultimately fatal) manifestations: progressive myoclonic epilepsy (PME) and renal failure (<a class="figpopup" href="/books/NBK333437/table/amrf.T.clinical_manifestations_of_amrf/?report=objectonly" target="object" rid-figpopup="figamrfTclinicalmanifestationsofamrf" rid-ob="figobamrfTclinicalmanifestationsofamrf">Table 2</a>); however, in some instances, renal failure is not observed. Thus, progressive myoclonus epilepsy without renal failure caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SCARB2</i> pathogenic variants is considered to be one end of the spectrum of AMRF [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.dibbens.2009.532">Dibbens et al 2009</a>, <a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>, <a class="bk_pop" href="#amrf.REF.guerrerol_pez.2012.1826">Guerrero-L&#x000f3;pez et al 2012</a>, <a class="bk_pop" href="#amrf.REF.zeigler.2014.210">Zeigler et al 2014</a>].</p><p>The age of onset varies, even within the same family.</p><ul><li class="half_rhythm"><div>Neurologic manifestations can appear before (in 1/3 of the cases), simultaneously, or after the renal manifestations. In juvenile AMRF onset is usually in the late teens or early twenties [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>].</div></li><li class="half_rhythm"><div>In some persons renal manifestations occur early (late childhood or early teens) and neurologic involvement much later (late 20s or early 30s) [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.hopfner.2011.134">Hopfner et al 2011</a>].</div></li><li class="half_rhythm"><div>In three persons of Japanese heritage who did not develop renal failure, neurologic manifestations appeared in the fifth or sixth decade [<a class="bk_pop" href="#amrf.REF.higashiyama.2013.552">Higashiyama et al 2013</a>, <a class="bk_pop" href="#amrf.REF.fu.2014.551">Fu et al 2014</a>].</div></li></ul><p>The neurologic and renal manifestations progress independently. Of note, the neurologic manifestations are not the result of a metabolic encephalopathy due to renal failure and are not improved by dialysis or by renal transplantation [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>].</p><p>Even in the same family, the number and order of appearance of the clinical manifestations can vary. Neurologic manifestations may occur first or in isolation in some family members and renal manifestations may be first or <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> in other family members [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>]. In some families, all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have neurologic manifestations and none develop renal failure [<a class="bk_pop" href="#amrf.REF.dibbens.2009.532">Dibbens et al 2009</a>, <a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>, <a class="bk_pop" href="#amrf.REF.guerrerol_pez.2012.1826">Guerrero-L&#x000f3;pez et al 2012</a>, <a class="bk_pop" href="#amrf.REF.fu.2014.551">Fu et al 2014</a>, <a class="bk_pop" href="#amrf.REF.perandones.2014">Perandones et al 2014</a>, <a class="bk_pop" href="#amrf.REF.zeigler.2014.210">Zeigler et al 2014</a>]; however, some affected family members have proteinuria [<a class="bk_pop" href="#amrf.REF.dibbens.2009.532">Dibbens et al 2009</a>, <a class="bk_pop" href="#amrf.REF.guerrerol_pez.2012.1826">Guerrero-L&#x000f3;pez et al 2012</a>] or reduced creatinine clearance [<a class="bk_pop" href="#amrf.REF.zeigler.2014.210">Zeigler et al 2014</a>].</p><p>The disease progresses relentlessly with neurologic deterioration (especially increasing severity of myoclonus) and renal failure leading to death within seven to 15 years after onset.</p><div id="amrf.T.clinical_manifestations_of_amrf" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Clinical Manifestations of AMRF</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK333437/table/amrf.T.clinical_manifestations_of_amrf/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__amrf.T.clinical_manifestations_of_amrf_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disease Onset</th><th id="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Major Manifestations</th><th id="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CNS Involvement</th><th id="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Renal Disease</th><th id="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other Possible Manifestations</th></tr></thead><tbody><tr><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Juvenile</b></td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PME and RF</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Tremor</div></li><li class="half_rhythm"><div>Progressive action myoclonus</div></li><li class="half_rhythm"><div>Myoclonus at rest</div></li><li class="half_rhythm"><div>Ataxia, dysarthria</div></li><li class="half_rhythm"><div>Severe epileptic photosensitivity</div></li><li class="half_rhythm"><div>GTCS (rare at onset; relatively infrequent even in later stages)</div></li></ul>
</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Proteinuria (progressing from mild to severe)</div></li><li class="half_rhythm"><div>Segmental GP and/or TP</div></li><li class="half_rhythm"><div>Renal failure</div></li></ul>
</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>PNP</div></li><li class="half_rhythm"><div>SNHL</div></li><li class="half_rhythm"><div>DCM</div></li></ul>
</td></tr><tr><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">PME</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Tremor</div></li><li class="half_rhythm"><div>Progressive action myoclonus</div></li><li class="half_rhythm"><div>Myoclonus at rest</div></li><li class="half_rhythm"><div>Ataxia, dysarthria</div></li><li class="half_rhythm"><div>Severe epileptic photosensitivity</div></li><li class="half_rhythm"><div>GTCS (infrequent at onset)</div></li></ul>
</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Mild proteinuria</div></li><li class="half_rhythm"><div>Mild decrease of creatinine clearance</div></li></ul>
</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>PNP</div></li><li class="half_rhythm"><div>Mild generalized muscle atrophy w/out fasciculations</div></li></ul>
</td></tr><tr><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">RF</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic manifestations as listed above may develop late in disease course.</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>May begin in early childhood or early teens</div></li><li class="half_rhythm"><div>Proteinuria, progressive</div></li><li class="half_rhythm"><div>Segmental GP</div></li><li class="half_rhythm"><div>TP</div></li><li class="half_rhythm"><div>Renal failure</div></li></ul>
</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Late</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PME</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Tremor</div></li><li class="half_rhythm"><div>Ataxia, dysarthria</div></li><li class="half_rhythm"><div>Progressive action myoclonus</div></li><li class="half_rhythm"><div>GTCS may occur infrequently</div></li><li class="half_rhythm"><div>Cognitive decline</div></li></ul>
</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td><td headers="hd_h_amrf.T.clinical_manifestations_of_amrf_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">DCM = dilated cardiomyopathy; GP = glomerulopathy; GTCS = generalized tonic-clonic seizures; PME = progressive myoclonus epilepsy; PNP = peripheral neuropathy; RF = renal failure; SNHL = sensorineural hearing loss; TP = tubulopathy</p></div></dd></dl></div></div></div><div id="amrf.Neurologic_Disease"><h4>Neurologic Disease</h4><p><b>Fine tremor.</b> The disease begins with bilateral fine tremor of the fingers that is noted at rest and increased by delicate movement such as writing, by intention of movement, and by maintaining an attitude in horizontal extension [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.vadlamudi.2006.1310">Vadlamudi et al 2006</a>]. The tremor can be relieved by alcohol [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.andermann.2011">Andermann 2011</a>, <a class="bk_pop" href="#amrf.REF.guerrerol_pez.2012.1826">Guerrero-L&#x000f3;pez et al 2012</a>]. It becomes progressively worse until it is masked by myoclonic jerks [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.vadlamudi.2006.1310">Vadlamudi et al 2006</a>].</p><p><b>Action myoclonus.</b> The fine tremor is followed by jerking movements first of the upper and then of the lower extremities. Referred to as action myoclonus, these jerking movements are typically triggered by movements or intended movements. They are asynchronous and of variable severity.</p><p>With time, myoclonic jerks involve the proximal limbs; their amplitude and number increases by movements of the limbs, typically by walking down stairs. Action myoclonus can also involve the trunk. Attempts at speaking and executed speech can induce myoclonus of the bulbar musculature, contributing to the dysarthria. There is no palatal myoclonus.</p><p>Action myoclonus, which is also reflex-sensitive to touch over the distal extremities, can be exacerbated by anxiety, excitement, stress, and fatigue [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.zeigler.2014.210">Zeigler et al 2014</a>] and by auditory stimuli [<a class="bk_pop" href="#amrf.REF.perandones.2012.1200">Perandones et al 2012</a>]. Some patients exhibit occasional myoclonus in response to startle [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>]. Of note, myoclonic jerks were significantly less frequent during pregnancy in one patient [<a class="bk_pop" href="#amrf.REF.amrom">Amrom et al, In press</a>].</p><p>Action myoclonus represents the most disabling manifestation: it prevents <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from being able to feed themselves and, thus, they become malnourished unless they receive assistance with feeding or are fed by artificial means. In the final stages, they may become bedridden or wheelchair bound. Swallowing difficulties can lead to aspiration pneumonia and death [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.vadlamudi.2006.1310">Vadlamudi et al 2006</a>].</p><p><b>Myoclonus at rest.</b> Subtle myoclonic movements of the eyelids, jaws, and perioral musculature appear at rest and while speaking. Ocular dysmetria can occur later in the disease course.</p><p><b>Clonic-tonic-clonic seizures,</b> which can be diurnal or nocturnal, begin with generalized clonic jerking with preserved consciousness and proceed to unconsciousness with tonic-clonic features. They occur infrequently, starting with one per annum initially [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>]. TV viewing or other light stimulation may trigger generalized myoclonic seizures or tonic-clonic seizures [<a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>]. Photosensitivity can become so severe that <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals choose to live in almost complete darkness [<a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>].</p><p><b>Ataxia and dysarthria,</b> common findings, can be distinguished from myoclonic jerks by the presence of the cerebellar abnormalities of pendular reflexes, abnormal rebound, and hypermetric ocular saccades.</p><p><b>Progressive myoclonus ataxia.</b> Some patients develop significant progressive ataxia before or after the appearance of myoclonus and, thus, have been reported to have "progressive myoclonus ataxia."</p><p>A woman age 29 years had a history of clumsiness in the lower limbs, mild gait instability, and difficulties in riding a bicycle beginning at age 21 years, two years before the onset of progressive myoclonus at age 23 years. Renal failure was evident at age 25 years, and bilateral severe SNHL was diagnosed at age 27 years [<a class="bk_pop" href="#amrf.REF.perandones.2012.1200">Perandones et al 2012</a>, <a class="bk_pop" href="#amrf.REF.perandones.2014">Perandones et al 2014</a>].</p><p>A woman age 22 years developed postural hand tremor exacerbated by fine voluntary movements and stress. The tremor slowly worsened with multifocal spontaneous and stimulus-sensitive myoclonic jerks. No other seizures were reported, and the EEG did not show any epileptic activity (of note, the patient was taking several antiepileptic medications). Ataxia was first reported when she was wheelchair bound at age 27 years. The co-occurrence of tremor, myoclonus, and ataxia in the same patient &#x02013; without generalized tonic-clonic seizures &#x02013; increases the complexity of the clinical picture of this disorder [<a class="bk_pop" href="#amrf.REF.guerrerol_pez.2012.1826">Guerrero-L&#x000f3;pez et al 2012</a>].</p><p><b>Peripheral neuropathy.</b> In some families, a sensorimotor peripheral neuropathy (most often predominantly demyelinating or more rarely axonal) may be present.</p><p>Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may be diagnosed with a predominantly demyelinating peripheral neuropathy before the onset of renal failure [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.costello.2009.898">Costello et al 2009</a>, <a class="bk_pop" href="#amrf.REF.dibbens.2011.812">Dibbens et al 2011</a>, <a class="bk_pop" href="#amrf.REF.hopfner.2011.134">Hopfner et al 2011</a>]. In the German Family I reported by <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al [2004]</a>, one family member with AMRF who was asymptomatic for polyneuropathy was initially found to have a predominantly axonal neuropathy by nerve conduction studies; several years later, he and his two affected sibs were reported to have predominantly demyelinating polyneuropathy [<a class="bk_pop" href="#amrf.REF.hopfner.2011.134">Hopfner et al 2011</a>].</p><p><b>Mild generalized muscle atrophy</b> was observed in one individual who exhibited mild generalized reduced tone and no fasciculations [<a class="bk_pop" href="#amrf.REF.zeigler.2014.210">Zeigler et al 2014</a>].</p></div><div id="amrf.Renal_Disease"><h4>Renal Disease</h4><p>Mild proteinuria may progress to nephrotic syndrome and ultimately to renal failure (<a class="figpopup" href="/books/NBK333437/table/amrf.T.clinical_manifestations_of_amrf/?report=objectonly" target="object" rid-figpopup="figamrfTclinicalmanifestationsofamrf" rid-ob="figobamrfTclinicalmanifestationsofamrf">Table 2</a>).</p><p>Dialysis and renal transplantation can prolong survival, but do not improve the neurologic features.</p></div><div id="amrf.Mental_Status"><h4>Mental Status</h4><p><b>Cognitive function.</b> Unlike individuals with most other types of progressive myoclonus epilepsy, the majority of individuals with AMRF syndrome remain mentally alert. However, dementia has been documented in two unrelated individuals of Japanese ancestry, one with the juvenile-onset form, and the other with the late-onset form, who have different <i>SCARB2</i> pathogenic variants [<a class="bk_pop" href="#amrf.REF.fu.2014.551">Fu et al 2014</a>].</p><p><b>Psychological complications.</b> Individuals with AMRF may exhibit somatic concerns or depressed mood, or may in exceptional cases commit suicide [<a class="bk_pop" href="#amrf.REF.amrom">Amrom et al, In press</a>].</p></div><div id="amrf.Other_Findings"><h4>Other Findings</h4><p><b>Cardiac disease.</b> In a German family, echocardiography revealed dilated cardiomyopathy in two of three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs at ages 14 and 21 years [<a class="bk_pop" href="#amrf.REF.hopfner.2011.134">Hopfner et al 2011</a>]. In addition, these sibs had sensorimotor peripheral neuropathy.</p><p><b>Hearing loss / deafness.</b> Frank or subclinical sensorineural hearing loss (SNHL) can be part of the spectrum of AMRF syndrome. Three individuals with AMRF had adult-onset SNHL, which was mild in one individual from one family [<a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>] and severe and asymmetric in an individual from a second family [<a class="bk_pop" href="#amrf.REF.perandones.2012.1200">Perandones et al 2012</a>], in which a sister had preclinical hearing loss [<a class="bk_pop" href="#amrf.REF.perandones.2014">Perandones et al 2014</a>].</p><p>Thus in the same family, the SNHL can be severe or subclinical or absent [<a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.perandones.2012.1200">Perandones et al 2012</a>, <a class="bk_pop" href="#amrf.REF.perandones.2014">Perandones et al 2014</a>].</p><p><b>Common causes of death in AMRF.</b> Sudden death may occur during or after a generalized epileptic seizure due to aspiration, severe myoclonus and unmanageable saliva, or an undetermined cause. Death can also occur due to aspiration pneumonia, renal failure, or rejection of a renal transplant [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.vadlamudi.2006.1310">Vadlamudi et al 2006</a>, <a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>].</p></div><div id="amrf.LateOnset_AMRF"><h4>Late-Onset AMRF</h4><p>Disease onset in the fifth or sixth decade has been reported in two Japanese families.</p><p><a class="bk_pop" href="#amrf.REF.higashiyama.2013.552">Higashiyama et al [2013]</a> reported one family with two sibs with AMRF without renal failure. The sister presented with myoclonic jerks at age 43 years; her older brother presented with gait difficulties at age 52 years. Both were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>SCARB2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.1385_1390del6insATGCATGCACC.</p><p><a class="bk_pop" href="#amrf.REF.fu.2014.551">Fu et al [2014]</a> reported single <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from two other Japanese families, one of whom (Patient 1) had late-onset disease. Patient 1 presented with onset of difficulties going up and down the stairs at age 45 years. Of note, he was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> as the two sibs reported by <a class="bk_pop" href="#amrf.REF.higashiyama.2013.552">Higashiyama et al [2013]</a>. Although the two families with the late-onset form are likely related as they originate from the same rural area, the precise relationship is unknown [Hiroshi Doi, 2014, personal communication; Hitoshi Takahashi, June 2014, personal communication]. Of note, Patient 2 reported by <a class="bk_pop" href="#amrf.REF.fu.2014.551">Fu et al [2014]</a> presented at age 20 years, was unrelated to Patient 1, and was homozygous for a different <i>SCARB2</i> pathogenic variant.</p></div><div id="amrf.Specialized_Studies"><h4>Specialized Studies</h4><p><b>EEG findings</b> [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>]. Background activity may be normal in some patients or show diffuse slowing at 6.5 to 7.5 Hz. Relatively low-voltage spike and spike-wave discharges, rather infrequent, bilaterally synchronous and generalized or confined to the central vertex or both occipital regions, increased by hyperventilation and intermittent photic stimulation, may be present.</p><p>Some of the brief spike potentials are difficult to distinguish from muscle potentials except that they are seen at the vertex where there is no muscle artefact. The electromyogram myoclonic potentials are sometimes associated with cerebral potentials and at other times occur independently, suggesting a subcortical origin with a secondary corticoreticular generalization.</p><p>Intermittent photic stimulation may produce whole-body myoclonus with multiple spikes in the EEG record associated with slow waves [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>]. These generalized spike-polyspike-wave bursts can outlast the duration of light stimulation [<a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>].</p><p>Myoclonic seizures can be triggered by eye closure and resolve by eye opening [<a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>].</p><p>Overnight sleep recording can show fast spikes over the vertex spreading to bilateral frontocentral regions during rapid eye movement (REM) sleep.</p><p>Follow up over the course of the disease shows a preserved alpha background activity at disease onset, with rare generalized or focal epileptiform discharges. Over the years, irregular slower theta and delta waves progressively intermix with the alpha waves, and the epileptic activity becomes more frequent [<a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>].</p><p><b>MRI findings.</b> Brain MRI may be normal or show mild diffuse cerebral and cerebellar atrophy [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.perandones.2012.1200">Perandones et al 2012</a>].</p><p><b>Electromyography findings.</b> Nerve conduction analysis can show slowed nerve conduction velocities and prolonged F-waves, consistent with a mixed, mainly demyelinating polyneuropathy [<a class="bk_pop" href="#amrf.REF.dibbens.2011.812">Dibbens et al 2011</a>, <a class="bk_pop" href="#amrf.REF.hopfner.2011.134">Hopfner et al 2011</a>, <a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>].</p><p>In one patient, concentric needle electromyography (EMG) was suggestive of chronic anterior horn involvement [<a class="bk_pop" href="#amrf.REF.zeigler.2014.210">Zeigler et al 2014</a>].</p><p><b>Brain histologic findings.</b> A constant and pathognomonic finding is the presence of small and large autofluorescent pigment granules up to 10 &#x000b5;m in size in astrocytes and in certain cells in the meninges. The pigment granules are more prominent in laminae I and II of the cerebral cortex, the globus pallidus and putamen, and the Bergmann astrocytes in the cerebellar cortex; they are not seen in the thalamus, brain stem nuclei, dentate nuclei of the cerebellum, or spinal cord gray matter. The granules are both separate from as well as adjacent to glial cell nuclei, suggesting that at least some were within astrocytes [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>, <a class="bk_pop" href="#amrf.REF.berkovic.2008.673">Berkovic et al 2008</a>].</p><p>Neurons contain normal amounts of lipofuscin and no pigment granules [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>]. In two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of Japanese ancestry extraneuronal brown pigment deposition, exclusively in astrocytic cytoplasm and surrounded by a membrane, was widely scattered throughout the brain [<a class="bk_pop" href="#amrf.REF.fu.2014.551">Fu et al 2014</a>].</p><p>Click <a href="/books/NBK333437/bin/amrf-spec_studies.pdf">here</a> for information about specialized studies for biologic and histologic findings.</p></div></div><div id="amrf.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No clear <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation is evident.</p><p>Disease severity may vary among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals within a family who have the same pathogenic variants. In some affected individuals, phenotypic variability may be explained by the presence of an additional <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in another epilepsy-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#amrf.REF.he.2014.598">He et al 2014</a>].</p></div><div id="amrf.Nomenclature"><h3>Nomenclature</h3><p>Action myoclonus &#x02013; renal failure (AMRF) syndrome has been referred to as:</p><ul><li class="half_rhythm"><div>Familial myoclonus with renal failure</div></li><li class="half_rhythm"><div>Progressive myoclonus epilepsy with renal failure</div></li><li class="half_rhythm"><div>Epilepsy, progressive myoclonic 4, with or without renal failure, EPM4. However, the presence or absence of renal failure represents only part of the clinical spectrum of AMRF.</div></li></ul><p>The term progressive myoclonus epilepsy (PME) covers a large group of diseases characterized by myoclonus, epilepsy, and progressive neurologic deterioration.</p></div><div id="amrf.Prevalence"><h3>Prevalence</h3><p>Exact prevalence figures are not available. To the authors' knowledge, 38 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from 26 families have been reported to date.</p><p>AMRF was first reported in several French-Canadian families [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>]; it occurs worldwide, including Europe; North, Central and South America; Australia; Asia; and the Middle-East.</p><p>Families without renal failure have been reported in Italy [<a class="bk_pop" href="#amrf.REF.dibbens.2009.532">Dibbens et al 2009</a>], Spain [<a class="bk_pop" href="#amrf.REF.guerrerol_pez.2012.1826">Guerrero-L&#x000f3;pez et al 2012</a>], Asia [<a class="bk_pop" href="#amrf.REF.higashiyama.2013.552">Higashiyama et al 2013</a>, <a class="bk_pop" href="#amrf.REF.fu.2014.551">Fu et al 2014</a>, <a class="bk_pop" href="#amrf.REF.he.2014.598">He et al 2014</a>], and the Middle-East [<a class="bk_pop" href="#amrf.REF.zeigler.2014.210">Zeigler et al 2014</a>].</p></div></div><div id="amrf.Genetically_Related_Allelic_Disorde"><h2 id="_amrf_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> mutation of <i>SCARB2</i>.</p><p>Of note, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> variants in <i>SCARB2</i> may modify the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <a href="/books/n/gene/gaucher/">Gaucher disease</a> [<a class="bk_pop" href="#amrf.REF.velayati.2011.1232">Velayati et al 2011</a>].</p><p>Click <a href="/books/NBK333437/bin/amrf-SCARB2_Parkinson_Dis.pdf">here</a> for information on possible population-based association of <i>SCARB2</i> and Parkinson disease.</p></div><div id="amrf.Differential_Diagnosis"><h2 id="_amrf_Differential_Diagnosis_">Differential Diagnosis</h2><p>At the onset of the disease, three non-progressive conditions should be considered in the differential diagnosis:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Cortical tremor syndrome.</b> At the onset of fine tremor, cortical tremor syndrome (see <a href="http://omim.org/phenotypicSeries/PS601068" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epilepsy, familial adult myoclonic: OMIM Phenotypic Series</a>) should be considered [<a class="bk_pop" href="#amrf.REF.ikeda.1990.1561">Ikeda et al 1990</a>, <a class="bk_pop" href="#amrf.REF.brown.2004.2151">Brown 2004</a>]. Cortical tremor syndrome, also referred to as familial adult myoclonic epilepsy (FAME) and familial cortical myoclonic tremor associated with epilepsy (FCMTE), is characterized by adult-onset cortical myoclonus of the extremities and seizures (mainly generalized tonic-clonic, less frequently myoclonic seizures or complex partial seizures) in 40% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. It usually has a favorable outcome.</div><div class="half_rhythm">Cortical tremor syndrome is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner in the majority of families. Five loci have been identified, three with autosomal dominant inheritance [<a class="bk_pop" href="#amrf.REF.guerrini.2001.2459">Guerrini et al 2001</a>, <a class="bk_pop" href="#amrf.REF.depienne.2010.2000">Depienne et al 2010</a>, <a class="bk_pop" href="#amrf.REF.striano.2010.669">Striano et al 2010</a>, <a class="bk_pop" href="#amrf.REF.coppola.2011.1245">Coppola et al 2011</a>, <a class="bk_pop" href="#amrf.REF.crompton.2012.474">Crompton et al 2012</a>]. In one family with autosomal dominant inheritance, a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ACMSD</i> has been identified [<a class="bk_pop" href="#amrf.REF.mart_mass_.2013.1399">Mart&#x000ed;-Mass&#x000f3; et al 2013</a>]. In one family with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance, <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>CNTN2</i> pathogenic variants have been identified [<a class="bk_pop" href="#amrf.REF.stogmann.2013.1155">Stogmann et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Juvenile myoclonic epilepsy (JME).</b> JME, which has a favorable outcome, should be considered at the onset of myoclonus. Individuals with JME have a normal neurologic examination and the EEG background activity is undisturbed. The myoclonus is not progressive [<a class="bk_pop" href="#amrf.REF.zifkin.2005.147">Zifkin et al 2005</a>, <a class="bk_pop" href="#amrf.REF.genton.2013.s8">Genton et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/myo-dystonia/"><b>Myoclonus-dystonia</b></a>
<b>(DYT11).</b> The association of myoclonus and dystonia suggests DYT11 [<a class="bk_pop" href="#amrf.REF.klein.2002">Klein 2002</a>]. Onset of myoclonus is usually in the first or second decade of life; the myoclonus is subcortical in origin [<a class="bk_pop" href="#amrf.REF.roze.2008.1010">Roze et al 2008</a>]; about half of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have segmental dystonia. No other neurologic features (in particular ataxia and cognitive deficits) are associated. DYT11 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Familial myoclonus-dystonia is associated with pathogenic variants in <i>SGCE</i> [<a class="bk_pop" href="#amrf.REF.zimprich.2001.66">Zimprich et al 2001</a>].</div></li></ul><p>In individuals with a PME <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> who do not have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SCARB2</i> pathogenic variants, the following disorders should be considered:</p><ul><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/epm1/"><b>Unverricht-Lundborg disease</b></a>
<b>(EPM1),</b> also referred to as <b>EPM1A,</b> is a progressive myoclonus epilepsy syndrome with an earlier age of onset and a slower rate of disease progression than AMRF; cognition is normal or mildly reduced [<a class="bk_pop" href="#amrf.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen et al 2008</a>, <a class="bk_pop" href="#amrf.REF.genton.2010.37">Genton 2010</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CSTB</i> (encoding cystatin B) are causative<i>.</i></div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/me-ataxia/"><b><i>PRICKLE1</i>-related progressive myoclonus epilepsy with ataxia</b></a>
<b>(EPM1B)</b> is a progressive myoclonus epilepsy-ataxia syndrome that presents in childhood. Ataxia begins at ages 4 to 5 years and evolves to PME with ataxia and mild or no cognitive decline. Impaired upward gaze has been observed in several <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#amrf.REF.berkovic.2005.652">Berkovic et al 2005</a>, <a class="bk_pop" href="#amrf.REF.bassuk.2008.572">Bassuk et al 2008</a>]. PRICKLE1-related PME with ataxia is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/lafora/"><b>Progressive myoclonus epilepsy, Lafora type</b></a> is considered in individuals with visual hallucinations (occipital epilepsy) and cognitive decline. Skin biopsy shows pathognomonic Lafora bodies [<a class="bk_pop" href="#amrf.REF.carpenter.1974.531">Carpenter et al 1974</a>, <a class="bk_pop" href="#amrf.REF.carpenter.1981.1564">Carpenter &#x00026; Karpati 1981</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>. Biallelic pathogenic variants in either <i>EPM2A</i> or <i>NHLRC1</i> (<i>EPM2B</i>) are causative [<a class="bk_pop" href="#amrf.REF.minassian.1998.171">Minassian et al 1998</a>, <a class="bk_pop" href="#amrf.REF.chan.2003.125">Chan et al 2003</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>EPM5</b> (OMIM <a href="http://omim.org/entry/613832" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613832</a>) is characterized by myoclonic seizures, cerebellar signs and deterioration of cognition as well as visual impairment [<a class="bk_pop" href="#amrf.REF.bird.1978.140">Bird and Shaw 1978</a>]. Some phenotypic findings may be similar to <a href="/books/n/gene/drpla/">dentatorubral-pallidoluysian atrophy</a> (DRPLA) [<a class="bk_pop" href="#amrf.REF.bird.1978.140">Bird &#x00026; Shaw 1978</a>, <a class="bk_pop" href="#amrf.REF.tsuji.2012.587">Tsuji 2012</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>PRICKLE2</i> are causative [<a class="bk_pop" href="#amrf.REF.tao.2011.138">Tao et al 2011</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Progressive <i>m</i>yoclonic <i>e</i>pilepsy and <i>a</i>taxia due to <i>KCNC1</i> channel mutation B (MEAK)</b> is clinically similar to Unverricht-Lundborg disease. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; a recurrent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>KCNC1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, c.959G&#x0003e;A (p.Arg320His) which causes loss of function of KV3.1, a subunit of the KV3 voltage-gated potassium ion channels, is causative [<a class="bk_pop" href="#amrf.REF.muona.2015.39">Muona et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Neuronal ceroid-lipofuscinoses</b> (<b>NCL).</b> In adult NCL (ANCL) (formerly called Kufs disease), initial signs and symptoms usually appear around age 30 years (range: teens to &#x0003e;50 years), with death occurring about ten years later. ANCL is clinically and genetically heterogeneous, and is inherited in either an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. It is distinguished from most other forms of NCL by preserved vision. The two major ANCL phenotypes are type A (the major form) and type B [<a class="bk_pop" href="#amrf.REF.berkovic.1988.27">Berkovic et al 1988</a>].</div><div class="half_rhythm">Note: ANCL type B is not part of the differential diagnosis of AMRF since it is characterized by behavioral abnormalities and dementia which may be associated with motor dysfunction, ataxia, extrapyramidal signs, and suprabulbar (brain stem) signs [<a class="bk_pop" href="#amrf.REF.berkovic.1988.27">Berkovic et al 1988</a>, <a class="bk_pop" href="#amrf.REF.smith.2013.1417">Smith et al 2013</a>].</div><div class="half_rhythm">ANCL type A is characterized by progressive myoclonic epilepsy with cognitive deterioration, ataxia, and late-occurring pyramidal and extrapyramidal signs. It can be inherited in either an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. The autosomal dominant forms have intraneuronal granular osmiophilic deposits (GRODs) observed on electron microscopy [<a class="bk_pop" href="#amrf.REF.burneo.2003.841">Burneo et al 2003</a>, <a class="bk_pop" href="#amrf.REF.nijssen.2003.574">Nijssen et al 2003</a>]. Some autosomal dominant forms are caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>DNAJC5</i> [<a class="bk_pop" href="#amrf.REF.noskov_.2011.241">Noskov&#x000e1; et al 2011</a>, <a class="bk_pop" href="#amrf.REF.cadieuxdion.2013.571">Cadieux-Dion et al 2013</a>, <a class="bk_pop" href="#amrf.REF.cadieuxdion.2014.470">Cadieux-Dion et al 2014</a>]. The autosomal recessive form is mainly caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CLN6</i> [<a class="bk_pop" href="#amrf.REF.arsov.2011.566">Arsov et al 2011</a>].</div><div class="half_rhythm">Other forms of ANCL type A, associated with visual loss, can result from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CLN1</i> [<a class="bk_pop" href="#amrf.REF.van_diggelen.2001.269">van Diggelen et al 2001</a>, <a class="bk_pop" href="#amrf.REF.ramadan.2007.387">Ramadan et al 2007</a>], <i>CLN5</i> [<a class="bk_pop" href="#amrf.REF.sleat.2009.1708">Sleat et al 2009</a>, <a class="bk_pop" href="#amrf.REF.xin.2010.565">Xin et al 2010</a>] or <i>GRN</i> [<a class="bk_pop" href="#amrf.REF.smith.2012.1102">Smith et al 2012</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div><div class="half_rhythm">A juvenile form of NCL with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance and GROD is associated with pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding palmitoyl-protein thioesterase (PPT), which are also seen in the infantile form of NCL (CLN1) [<a class="bk_pop" href="#amrf.REF.mitchison.1998.291">Mitchison et al 1998</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Sialidosis type 1</b> (OMIM <a href="http://omim.org/entry/256550" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">256550</a>) is characterized by PME with cognitive decline and can be assessed with neuroophthalmologic examination, including electroretinography [<a class="bk_pop" href="#amrf.REF.boustany.2013.583">Boustany 2013</a>, <a class="bk_pop" href="#amrf.REF.mink.2013.1101">Mink et al 2013</a>]. Sialidosis type 1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner and caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants of <i>NEU1</i> [<a class="bk_pop" href="#amrf.REF.bonten.2000.2715">Bonten et al 2000</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/merrf/"><b>MERRF</b></a>
<b>(myoclonic epilepsy with ragged red fibers)</b> is a multisystem disorder characterized by myoclonus, which is often the first symptom, followed by generalized epilepsy, ataxia, weakness, and dementia. In individuals with MERRF, blood and cerebrospinal fluid concentrations of lactate and pyruvate are commonly elevated at rest and increase excessively after moderate activity [<a class="bk_pop" href="#amrf.REF.bindoff.2012.92">Bindoff &#x00026; Engelsen 2012</a>, <a class="bk_pop" href="#amrf.REF.finsterer.2012.316">Finsterer &#x00026; Zarrouk Mahjoub 2012</a>]. MERRF is caused by pathogenic variants in mtDNA and is transmitted by maternal inheritance</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/gaucher/"><b>Gaucher disease type 3</b></a><b>,</b> characterized by the presence of primary neurologic disease, may have onset before age two years, but often has a more slowly progressive course, with survival into the third or fourth decade. Saccade initiation failure is a common and early manifestation &#x02013; suggestive of early dysfunction of supranuclear ocular motor control &#x02013; and can be detected during induced optokinetic or vestibular nystagmus [<a class="bk_pop" href="#amrf.REF.harris.1999.289">Harris et al 1999</a>]. Gaucher disease is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner and is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>GBA</i> (encoding the enzyme &#x003b2;-glucocerebrosidase) [<a class="bk_pop" href="#amrf.REF.tsuji.1987.570">Tsuji et al 1987</a>, <a class="bk_pop" href="#amrf.REF.dahl.1988.296">Dahl et al 1988</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Familial encephalopathy with neuroserpin inclusion bodies (FENIB)</b> (OMIM <a href="http://omim.org/entry/604218" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604218</a>). Age of onset and clinical manifestations vary considerably. The spectrum of clinical phenotypes ranges from cognitive decline/dementia, dysarthria, and tremors to various forms of refractory epilepsy including progressive myoclonus epilepsy (PME) and focal or generalized seizures. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>SERPINI1</i> are causative [<a class="bk_pop" href="#amrf.REF.hagen.2011.575">Hagen et al 2011</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/drpla/"><b>DRPLA</b></a>
<b>(dentatorubral-pallidoluysian atrophy).</b> Individuals with juvenile onset (age &#x0003c;20 years) of DRPLA present with PME and associated progressive cognitive deterioration and behavioral changes; whereas those with adult onset (age &#x0003e;20 years) of DRPLA present with ataxia, choreoathetosis, and dementia. DRPLA is relatively more common among the Japanese than in other ethnic populations [<a class="bk_pop" href="#amrf.REF.takano.1998.1060">Takano et al 1998</a>]. DRPLA is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner and expansion of a CAG trinucleotide/polyglutamine tract in <i>ATN1</i> is causative [<a class="bk_pop" href="#amrf.REF.tsuji.2012.587">Tsuji 2012</a>].</div></li></ul><p>See <a href="http://omim.org/phenotypicSeries/PS254800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epilepsy, progressive myoclonic: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p><p><b>Charcot-Marie-Tooth neuropathy with focal segmental glomerulonephritis</b> (OMIM <a href="http://omim.org/entry/614455" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614455</a>) should be considered in persons with peripheral neuropathy and glomerulonephritis [<a class="bk_pop" href="#amrf.REF.boyer.2011.2377">Boyer et al 2011</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>INF2</i> are causative.</p></div><div id="amrf.Management"><h2 id="_amrf_Management_">Management</h2><div id="amrf.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with action myoclonus &#x02013; renal failure (AMRF) syndrome, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Clinical evaluation including cognitive function and school performance, emotional features, eye movements, coordination, handwriting, walking</div></li><li class="half_rhythm"><div>Examination of myoclonus including evaluation at rest, with action, and in response to stimuli</div></li><li class="half_rhythm"><div>EEG evaluation including photosensitivity before therapy is initiated, as it is most characteristic before the use of anticonvulsant medication</div></li><li class="half_rhythm"><div>Renal function</div></li><li class="half_rhythm"><div>Audiogram and brain stem auditory evoked potentials (BAEPs) to assess the possibility of clinical or subclinical sensorineural hearing loss [<a class="bk_pop" href="#amrf.REF.rubboli.2011.2356">Rubboli et al 2011</a>, <a class="bk_pop" href="#amrf.REF.perandones.2012.1200">Perandones et al 2012</a>, <a class="bk_pop" href="#amrf.REF.perandones.2014">Perandones et al 2014</a>]</div></li><li class="half_rhythm"><div>Nerve conduction velocities (NCV) and needle electromyography (EMG)</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="amrf.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Neurologic manifestations.</b> Symptomatic pharmacologic and psychosocial support is the mainstay of care for the neurologic manifestations. Response to treatment is variable and may deteriorate over time, necessitating rehabilitative management.</p><ul><li class="half_rhythm"><div class="half_rhythm">Valproic acid, the first drug of choice, diminishes myoclonus and the frequency of generalized seizures.</div></li><li class="half_rhythm"><div class="half_rhythm">Clonazepam may be used as add-on therapy for the treatment of myoclonic seizures.</div></li><li class="half_rhythm"><div class="half_rhythm">Levetiracetam appearss to be effective for both myoclonus and generalized seizures, and is recommended in women of child bearing age.</div><div class="half_rhythm">Note: Lamotrigine is not effective in controlling the myoclonus, and may aggravate myoclonus in some patients [<a class="bk_pop" href="#amrf.REF.guerrini.1998.508">Guerrini et al 1998</a>].</div></li></ul><p><b>Renal manifestations.</b> Renal insufficiency requires dialysis but response to treatment is poor, and renal transplantation is often necessary.</p></div><div id="amrf.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Standard measures for prevention of aspiration pneumonia and sudden unexpected death in epilepsy (SUDEP) should be followed; offering psychosocial support may be helpful.</p></div><div id="amrf.Surveillance"><h3>Surveillance</h3><p>Lifelong clinical follow up should include the following:</p><ul><li class="half_rhythm"><div>Neurologic</div><ul><li class="half_rhythm"><div>Monitoring of antiepileptic drug treatment (drug levels and clinical assessment of biological effects);</div></li><li class="half_rhythm"><div>Periodic assessment of hearing by audiograms and BAEPs and of the peripheral nerves by NCV and needle EMG.</div></li></ul></li><li class="half_rhythm"><div>Renal function monitoring by measurement of: blood pressure; body weight; serum concentrations of creatinine, albumin, and cholesterol; 24-hour urinary protein; and creatinine clearance</div></li></ul></div><div id="amrf.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Diphenylhydantoin, carbamazepine, oxcarbazepine, and possibly lamotrigine increase myoclonus and should be avoided in any individual with progressive myoclonic epilepsy (PME), including AMRF.</p></div><div id="amrf.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#amrf.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="amrf.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Some antiepileptic drugs can lead to an increased risk of malformations, growth retardation, or neurodevelopmental disabilities in exposed fetuses. However, when pregnant women experience prolonged seizures during pregnancy, the risk of adverse fetal outcomes is increased. Therefore, it is recommended that women with a known seizure disorder continue to take antiepileptic drugs during pregnancy. Standard measures for prevention of fetopathy should be followed. These include:</p><ul><li class="half_rhythm"><div>Possible changes of medication prior to pregnancy;</div></li><li class="half_rhythm"><div>Spacing of the antiepileptic drugs into four doses a day or taking extended release medications, so that the drug levels do not have significant peaks or troughs;</div></li><li class="half_rhythm"><div>Monitoring the dosages and drug levels of antiepileptic drugs during pregnancy and after the delivery.</div></li></ul><p>In addition, folic acid should be prescribed at 1 mg/day for all women of childbearing age and increased to 5 mg/day when planning a pregnancy (ideally 3 months prior to conception) and during the pregnancy, in order to prevent possible neural tube defects and other <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> malformations that can be associated with fetal exposure to antiepileptic drugs.</p></div><div id="amrf.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A trial of enzyme replacement therapy (ERP) with imiglucerase (60 U/kg every two weeks) in two sibs with AMRF for a period of one year did not improve the clinical status. Substrate reduction therapy (SRT) with miglustat (600 mg daily) administered to one of the two sibs resulted in a significant reduction of myoclonus [<a class="bk_pop" href="#amrf.REF.chaves.2011.738">Chaves et al 2011</a>].</p><p>Search <a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Trials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="amrf.Genetic_Counseling"><h2 id="_amrf_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="amrf.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Action myoclonus - renal failure (AMRF) syndrome is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="amrf.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>SCARB2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with action myoclonus-renal failure syndrome are obligate heterozygotes (carriers) for a <i>SCARB2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the reproductive partner of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>SCARB2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the offspring have a 50% chance of being affected and a 50% chance of being a carrier.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="amrf.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>SCARB2</i> pathogenic variants in the family.</p></div><div id="amrf.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="amrf.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SCARB2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for AMRF are possible.</p><p><b>Fetal ultrasound examination.</b> Prenatal testing by level 2 ultrasound examination does <b>NOT</b> detect AMRF, as disease onset is usually in the late teens or early twenties.</p></div></div><div id="amrf.Resources"><h2 id="_amrf_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Epilepsy Society (AES)</b></div><div><a href="http://www.aesnet.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aesnet.org</a></div></li><li class="half_rhythm"><div><b>American Kidney Fund</b></div><div>11921 Rockville Pike</div><div>Suite 300</div><div>Rockville MD 20852</div><div><b>Phone:</b> 866-300-2900</div><div><b>Email:</b> helpline@kidneyfund.org</div><div><a href="http://www.kidneyfund.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kidneyfund.org</a></div></li><li class="half_rhythm"><div><b>Canadian Epilepsy Alliance</b></div><div>Canada</div><div><b>Phone:</b> 1-866-EPILEPSY (1-866-374-5377)</div><div><a href="http://epilepsymatters.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.epilepsymatters.com</a></div></li><li class="half_rhythm"><div><b>Citizens United for Research in Epilepsy (CURE)</b></div><div><a href="http://www.cureepilepsy.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cureepilepsy.org</a></div></li><li class="half_rhythm"><div><b>Epilepsy Foundation</b></div><div>8301 Professional Place East</div><div>Suite 200</div><div>Landover MD 20785-7223</div><div><b>Phone:</b> 800-332-1000 (toll-free)</div><div><b>Email:</b> ContactUs@efa.org</div><div><a href="https://www.epilepsy.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.epilepsy.com</a></div></li><li class="half_rhythm"><div><b>Kidney Foundation of Canada</b></div><div>310-5160 Decarie Blvd.</div><div>Montreal Ontario H3X 2H9 </div><div>Canada</div><div><b>Phone:</b> 800-361-7494 (toll-free); 514-369-4806</div><div><b>Fax:</b> 514-369-2472 </div><div><b>Email:</b> info@kidney.ca</div><div><a href="http://www.kidney.on.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kidney.ca</a></div></li><li class="half_rhythm"><div><b>NephCure Kidney International</b></div><div> PA </div><div><b>Phone:</b> 866-NephCure; 866-637-4287</div><div><b>Email:</b> info@nephcure.org</div><div><a href="http://nephcure.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">nephcure.org</a></div></li></ul></div><div id="amrf.Molecular_Genetics"><h2 id="_amrf_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="amrf.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Action Myoclonus - Renal Failure Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK333437/table/amrf.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__amrf.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_amrf.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_amrf.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_amrf.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_amrf.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_amrf.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_amrf.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_amrf.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/950" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SCARB2</i></a></td><td headers="hd_b_amrf.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=950" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">4q21<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_amrf.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q14108" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Lysosome membrane protein 2</a></td><td headers="hd_b_amrf.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/SCARB2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SCARB2 database</a></td><td headers="hd_b_amrf.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SCARB2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SCARB2</a></td><td headers="hd_b_amrf.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SCARB2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SCARB2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="amrf.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="amrf.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Action Myoclonus - Renal Failure Syndrome (<a href="/omim/254900,602257" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK333437/table/amrf.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__amrf.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/254900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">254900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPILEPSY, PROGRESSIVE MYOCLONIC, 4, WITH OR WITHOUT RENAL FAILURE; EPM4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602257" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602257</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SCAVENGER RECEPTOR CLASS B, MEMBER 2; SCARB2</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>SCARB2</i> contains 5.5 kb with 12 exons and codes for two transcript variants; the longer variant is <a href="/nuccore/NM_005506.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_005506.3</a>. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK333437/#amrf.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> A few sequence alterations that are not believed to have a primary role in disease causation have been found in unaffected individuals [Dibbens et al, unpublished data]. The extent to which these variants may influence the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> or clinical disease expression remains to be established.</p><p><b>Pathogenic variants.</b> Known pathogenic variants include <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, frameshift, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, leading to retention of SCARB2 protein (previously known as LIMP-2) in the endoplasmic reticulum, but differentially affecting the binding to &#x003b2;-glucocerebrosidase (&#x003b2;-GC) [<a class="bk_pop" href="#amrf.REF.blanz.2010.563">Blanz et al 2010</a>]. To the authors' knowledge, all pathogenic variants identified to date are <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants.</p><p>See <a class="figpopup" href="/books/NBK333437/table/amrf.T.scarb2_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figamrfTscarb2pathogenicvariantsdiscus" rid-ob="figobamrfTscarb2pathogenicvariantsdiscus">Table 3</a> and <a href="/books/NBK333437/bin/amrf-table4.pdf">Table 4</a> (pdf).</p><div id="amrf.T.scarb2_pathogenic_variants_discus" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>SCARB2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK333437/table/amrf.T.scarb2_pathogenic_variants_discus/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__amrf.T.scarb2_pathogenic_variants_discus_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_amrf.T.scarb2_pathogenic_variants_discus_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_amrf.T.scarb2_pathogenic_variants_discus_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_amrf.T.scarb2_pathogenic_variants_discus_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_amrf.T.scarb2_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.862C&#x0003e;T</td><td headers="hd_h_amrf.T.scarb2_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln288Ter</td><td headers="hd_h_amrf.T.scarb2_pathogenic_variants_discus_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_005506.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_005506<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_005497.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_005497<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_amrf.T.scarb2_pathogenic_variants_discus_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1187+3insT</td><td headers="hd_h_amrf.T.scarb2_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">Variants included are found in persons of French-Canadian origin; see <a class="figpopup" href="/books/NBK333437/table/amrf.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figamrfTmoleculargenetictestingusedin" rid-ob="figobamrfTmoleculargenetictestingusedin">Table 1</a>, footnote 5.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The protein encoded by <i>SCARB2</i> (scavenger receptor class B, member 2) is a glycosylated 478-residue type III transmembrane protein that belongs to the CD36 family of scavenger receptors and is found in all cell types.</p><p>SCARB2 (previously known as LIMP-2) has two known physiologic functions related to lysosome biology:</p><ul><li class="half_rhythm"><div>First, it is a major lysosomal integral membrane protein playing an important role in the biogenesis and maintenance of endosomes/lysosomes and interaction with the vesicle fission/fusion machinery [<a class="bk_pop" href="#amrf.REF.eskelinen.2003.137">Eskelinen et al 2003</a>].</div></li><li class="half_rhythm"><div>Second, it is a specific trafficking receptor of &#x003b2;-glucocerebrosidase (&#x003b2;-GC), the enzyme deficient in <a href="/books/n/gene/gaucher/">Gaucher disease</a> [<a class="bk_pop" href="#amrf.REF.reczek.2007.770">Reczek et al 2007</a>]. It binds &#x003b2;-GC for transfer from the endoplasmic reticulum to the lysosome in a mannose-6-phosphate independent manner. The released &#x003b2;-GC remains in the endosome/lysosome whereas SCARB-2 then integrates in the limiting membrane of lysosomes, and is therefore also known as lysosomal integral membrane protein type 2 or LIMP-2 [<a class="bk_pop" href="#amrf.REF.reczek.2007.770">Reczek et al 2007</a>, <a class="bk_pop" href="#amrf.REF.braulke.2009.605">Braulke &#x00026; Bonifacino 2009</a>, <a class="bk_pop" href="#amrf.REF.blanz.2010.563">Blanz et al 2010</a>].</div></li><li class="half_rhythm"><div>Third, LIMP-2 has recently been found to represent a substrate for cathepsin-F, the enzyme involved in <a href="/books/n/gene/ncl/">ANCL</a> (Kufs disease) type B, suggesting that there may be links between the pathogenesis of different forms of PME.</div></li></ul><p>In addition, an extralysosomal function has been discovered in mice, human hearts, and myocytes in vivo, in which LIMP-2 has been identified as an important component of the structural organization of the cardiac myocyte intercalated disc, in particular adherens junctions, where it interacts with N-cadherin [<a class="bk_pop" href="#amrf.REF.schroen.2007.1227">Schroen et al 2007</a>].</p><p>SCARB2 protein also functions as a receptor for various viruses.</p><ul><li class="half_rhythm"><div>It performs viral binding, viral internalization, and viral uncoating of enterovirus 71 (EV71), the virus causing hand, foot, and mouth disease in young children or occasionally severe brain stem encephalitis and acute flaccid paralysis [<a class="bk_pop" href="#amrf.REF.yamayoshi.2009.798">Yamayoshi et al 2009</a>, <a class="bk_pop" href="#amrf.REF.yamayoshi.2012a.32">Yamayoshi et al 2012a</a>, <a class="bk_pop" href="#amrf.REF.yamayoshi.2012b.5686">Yamayoshi et al 2012b</a>, <a class="bk_pop" href="#amrf.REF.yamayoshi.2013.3335">Yamayoshi et al 2013</a>].</div></li><li class="half_rhythm"><div>It is also a receptor of the coxsackievirus A7, A14, and A16 [<a class="bk_pop" href="#amrf.REF.yamayoshi.2012b.5686">Yamayoshi et al 2012b</a>].</div></li></ul><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Action myoclonus &#x02013; renal failure syndrome (AMRF) is caused by deficiency of the SCARB2 protein.</p><p>In AMRF, the beta-glucocerebrosidase (&#x003b2;-GC) structure itself is not <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, but its receptor in the trans-Golgi network (TGN) is abnormal, therefore altering its trafficking along its biosynthetic pathway. Biochemical analysis reveals a severe deficiency of &#x003b2;-GC in skin fibroblasts despite normal enzyme activity on standard leukocyte screening assays (Family D in <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al [2004]</a>; unpublished data) [<a class="bk_pop" href="#amrf.REF.balreira.2008.2238">Balreira et al 2008</a>, <a class="bk_pop" href="#amrf.REF.zeigler.2014.210">Zeigler et al 2014</a>].</p><p>This selective tissue involvement could be due to variable expression of the SCARB2 protein or to a variable pathway for the transport of &#x003b2;-GC, specific to tissue. Another hypothesis could be that SCARB2 is also a transporter of other as-yet unidentified proteins that also accumulate and/or are secreted in excess [<a class="bk_pop" href="#amrf.REF.amrom">Amrom et al, in press</a>].</p><p>AMRF is remarkable for the preservation of normal intelligence in the majority of patients. This could be explained by the observation of extraneuronal but no intraneuronal storage of autofluorescent pigmented material [<a class="bk_pop" href="#amrf.REF.andermann.1986.87">Andermann et al 1986</a>, <a class="bk_pop" href="#amrf.REF.badhwar.2004.2173">Badhwar et al 2004</a>]. However, two Japanese patients with AMRF developed dementia; it is unclear whether this is linked to AMRF or whether these patients had a second disease [<a class="bk_pop" href="#amrf.REF.fu.2014.551">Fu et al 2014</a>]. Autofluorescent pigmented granules were observed in the cytoplasm of the astrocytes in these patients. Neuropathologic studies are needed in order to identify the nature of the storage material and to better localize the cellular organelles at the site of storage.</p><p><b>Animal models.</b> The <i>limp-2</i>/<i>scarb2</i><sup>-/-</sup> knockout mice showed a triad encompassing pelvic junction obstruction, deafness, and peripheral demyelinating neuropathy [<a class="bk_pop" href="#amrf.REF.gamp.2003.631">Gamp et al 2003</a>].</p><p>Fluorescence immunohistochemical studies in these mice showed that deafness was due to an early loss of potassium channel KCNQ1/KCNE1 surface expression in marginal cells of the stria vascularis in the cochlea [<a class="bk_pop" href="#amrf.REF.knipper.2006.73">Knipper et al 2006</a>]. In vivo studies in mice lacking limp-2 have shown that &#x003b2;-GC is no longer sorted to lysosomes but is secreted into the extracellular environment [<a class="bk_pop" href="#amrf.REF.reczek.2007.770">Reczek et al 2007</a>].</p><p>In the <i>limp-2</i>
null mice, embryologic cardiac development is normal; however, these mice fail to mount a hypertrophic cardiac response to AngII-induced hypertension, and develop dilated cardiomyopathy. limp-2 protein was thus shown to not only be an important lysosomal protein but also to be an important part of the intercalated disc of the heart and crucial for the hypertrophic response to cardiac loading [<a class="bk_pop" href="#amrf.REF.schroen.2007.1227">Schroen et al 2007</a>].</p></div><div id="amrf.References"><h2 id="_amrf_References_">References</h2><div id="amrf.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.amrom">Amrom D, Andermann F, Dibbens L, Berkovic S, Schwake M, Saftig P, Andermann E. Action myoclonus with renal failure syndrome (AMRF). In: Andermann E, Avanzini G, Genton P, Minassian B, eds. <em>Progressive Myoclonus Epilepsies</em>. New Barnet, UK: John Libbey; in press.</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.andermann.1986.87">Andermann E, Andermann F, Carpenter S, Wolfe LS, Nelson R, Patry G, Boileau J. Action myoclonus-renal failure syndrome: a previously unrecognized neurological disorder unmasked by advances in nephrology. <span><span class="ref-journal">Adv Neurol. </span>1986;<span class="ref-vol">43</span>:87–103.</span> [<a href="/pubmed/3946122" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3946122</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.andermann.2011">Andermann E. Action myoclonus &#x02013; renal failure syndrome. In: Shorvon SD, Andermann F, Guerrini R, eds. <em>The Causes of Epilepsy: Common and Uncommon Causes in Adults and Children</em>. Cambridge, UK: Cambridge University Press; 2011:169-71.</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.arsov.2011.566">Arsov T, Smith KR, Damiano J, Franceschetti S, Canafoglia L, Bromhead CJ, Andermann E, Vears DF, Cossette P, Rajagopalan S, McDougall A, Sofia V, Farrell M, Aguglia U, Zini A, Meletti S, Morbin M, Mullen S, Andermann F, Mole SE, Bahlo M, Berkovic SF. Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. <span><span class="ref-journal">Am J Hum Genet. </span>2011;<span class="ref-vol">88</span>:566–73.</span> [<a href="/pmc/articles/PMC3146726/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3146726</span></a>] [<a href="/pubmed/21549341" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21549341</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.badhwar.2004.2173">Badhwar A, Berkovic SF, Dowling JP, Gonzales M, Narayanan S, Brodtmann A, Berzen L, Caviness J, Trenkwalder C, Winkelmann J, Rivest J, Lambert M, Hernandez-Cossio O, Carpenter S, Andermann F, Andermann E. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. <span><span class="ref-journal">Brain. </span>2004;<span class="ref-vol">127</span>:2173–82.</span> [<a href="/pubmed/15364701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15364701</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.balreira.2008.2238">Balreira A, Gaspar P, Caiola D, Chaves J, Beirao I, Lima JL, Azevedo JE, Miranda MC. A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. <span><span class="ref-journal">Hum Mol Genet. </span>2008;<span class="ref-vol">17</span>:2238–43.</span> [<a href="/pubmed/18424452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18424452</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.bassuk.2008.572">Bassuk AG, Wallace RH, Buhr A, Buller AR, Afawi Z, Shimojo M, Miyata S, Chen S, Gonzalez-Alegre P, Griesbach HL, Wu S, Nashelsky M, Vladar EK, Antic D, Ferguson PJ, Cirak S, Voit T, Scott MP, Axelrod JD, Gurnett C, Daoud AS, Kivity S, Neufeld MY, Mazarib A, Straussberg R, Walid S, Korczyn AD, Slusarski DC, Berkovic SF, El-Shanti HI. A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">83</span>:572–81.</span> [<a href="/pmc/articles/PMC2668041/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2668041</span></a>] [<a href="/pubmed/18976727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18976727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.berkovic.1988.27">Berkovic SF, Carpenter S, Andermann F, Andermann E, Wolfe LS. Kuf's disease: a critical reappraisal. <span><span class="ref-journal">Brain. </span>1988;<span class="ref-vol">111</span>:27–62.</span> [<a href="/pubmed/3284607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3284607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.berkovic.2008.673">Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M, Vears DF, Lullmann-Rauch R, Blanz J, Zhang KW, Stankovich J, Kalnins RM, Dowling JP, Andermann E, Andermann F, Faldini E, D'Hooge R, Vadlamudi L, Macdonell RA, Hodgson BL, Bayly MA, Savige J, Mulley JC, Smyth GK, Power DA, Saftig P, Bahlo M. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">82</span>:673–84.</span> [<a href="/pmc/articles/PMC2427287/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2427287</span></a>] [<a href="/pubmed/18308289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18308289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.berkovic.2005.652">Berkovic SF, Mazarib A, Walid S, Neufeld MY, Manelis J, Nevo Y, Korczyn AD, Yin J, Xiong L, Pandolfo M, Mulley JC, Wallace RH. A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. <span><span class="ref-journal">Brain. </span>2005;<span class="ref-vol">128</span>:652–8.</span> [<a href="/pubmed/15634728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15634728</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.bindoff.2012.92">Bindoff LA, Engelsen BA. Mitochondrial diseases and epilepsy. <span><span class="ref-journal">Epilepsia. </span>2012;<span class="ref-vol">53</span> Suppl 4:92–7.</span> [<a href="/pubmed/22946726" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22946726</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.bird.1978.140">Bird TD, Shaw CM. Progressive myoclonus and epilepsy with dentatorubral degeneration: a clinicopathological study of the Ramsay Hunt syndrome. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1978;<span class="ref-vol">41</span>:140–9.</span> [<a href="/pmc/articles/PMC492982/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC492982</span></a>] [<a href="/pubmed/632821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 632821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.blanz.2010.563">Blanz J, Groth J, Zachos C, Wehling C, Saftig P, Schwake M. Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase. <span><span class="ref-journal">Hum Mol Genet. </span>2010;<span class="ref-vol">19</span>:563–72.</span> [<a href="/pubmed/19933215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19933215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.bonten.2000.2715">Bonten EJ, Arts WF, Beck M, Covanis A, Donati MA, Parini R, Zammarchi E, d'Azzo A. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. <span><span class="ref-journal">Hum. Molec. Genet. </span>2000;<span class="ref-vol">9</span>:2715–25.</span> [<a href="/pubmed/11063730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11063730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.boustany.2013.583">Boustany RM. Lysosomal storage diseases--the horizon expands. <span><span class="ref-journal">Nat Rev Neurol. </span>2013;<span class="ref-vol">9</span>:583–98.</span> [<a href="/pubmed/23938739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23938739</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.boyer.2011.2377">Boyer O, Nevo F, Plaisier E, Funalot B, Gribouval O, Benoit G. Huynh Cong E, Arrondel C, T&#x000ea;te MJ, Montjean R, Richard L, Karras A, Pouteil-Noble C, Balafrej L, Bonnardeaux A, Canaud G, Charasse C, Dantal J, Deschenes G, Deteix P, Dubourg O, Petiot P, Pouthier D, Leguern E, Guiochon-Mantel A, Broutin I, Gubler MC, Saunier S, Ronco P, Vallat JM, Alonso MA, Antignac C, Mollet G. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">365</span>:2377–88.</span> [<a href="/pubmed/22187985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22187985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.braulke.2009.605">Braulke T, Bonifacino JS. Sorting of lysosomal proteins. <span><span class="ref-journal">Biochim Biophys Acta. </span>2009;<span class="ref-vol">1793</span>:605–14.</span> [<a href="/pubmed/19046998" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19046998</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.brown.2004.2151">Brown P. Action myoclonus-renal failure syndrome: the definitive clinico-pathological description. <span><span class="ref-journal">Brain. </span>2004;<span class="ref-vol">127</span>:2151–2.</span> [<a href="/pubmed/15385427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15385427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.burneo.2003.841">Burneo JG, Arnold T, Palmer CA, Kuzniecky RI, Oh SJ, Faught E. Adult-onset neuronal ceroid lipofuscinosis (Kufs disease) with autosomal dominant inheritance in Alabama. <span><span class="ref-journal">Epilepsia. </span>2003;<span class="ref-vol">44</span>:841–6.</span> [<a href="/pubmed/12790899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12790899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.cadieuxdion.2013.571">Cadieux-Dion M, Andermann E, Lachance-Touchette P, Ansorge O, Meloche C, Barnab&#x000e9; A, Kuzniecky RI, Andermann F, Faught E, Leonberg S, Damiano JA, Berkovic SF, Rouleau GA, Cossette P. Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease. <span><span class="ref-journal">Clin Genet. </span>2013;<span class="ref-vol">83</span>:571–5.</span> [<a href="/pubmed/22978711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22978711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.cadieuxdion.2014.470">Cadieux-Dion M, Turcotte-Gauthier M, Noreau A, Martin C, Meloche C, Gravel M, Drouin CA, Rouleau GA, Nguyen DK, Cossette P. Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia. <span><span class="ref-journal">JAMA Neurol. </span>2014;<span class="ref-vol">71</span>:470–5.</span> [<a href="/pubmed/24566826" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24566826</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.carpenter.1974.531">Carpenter S, Karpati G, Andermann F, Jacob JC, Andermann E. Lafora's disease: peroxisomal storage in skeletal muscle. <span><span class="ref-journal">Neurology. </span>1974;<span class="ref-vol">24</span>:531–8.</span> [<a href="/pubmed/4220225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4220225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.carpenter.1981.1564">Carpenter S, Karpati G. Sweat gland duct cells in Lafora disease: diagnosis by skin biopsy. <span><span class="ref-journal">Neurology. </span>1981;<span class="ref-vol">31</span>:1564–8.</span> [<a href="/pubmed/6796905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6796905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.chan.2003.125">Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJ, Bohlega S, Andermann E, Rouleau GA, Delgado-Escueta AV, Minassian BA, Scherer SW. Mutations in NHLRC1 cause progressive myoclonus epilepsy. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">35</span>:125–7.</span> [<a href="/pubmed/12958597" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12958597</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.chaves.2011.738">Chaves J, Beirao I, Balreira A, Gaspar P, Caiola D, Sa-Miranda MC, Lima JL. Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency: clinical report of two siblings. <span><span class="ref-journal">Seizure. </span>2011;<span class="ref-vol">20</span>:738–40.</span> [<a href="/pubmed/21782476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21782476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.coppola.2011.1245">Coppola A, Santulli L, Del Gaudio L, Minetti C, Striano S, Zara F, Striano P. Natural history and long-term evolution in families with autosomal dominant cortical tremor, myoclonus, and epilepsy. <span><span class="ref-journal">Epilepsia. </span>2011 Jul;<span class="ref-vol">52</span>(7):1245–50.</span> [<a href="/pubmed/21426326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21426326</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.costello.2009.898">Costello DJ, Chiappa KH, Siao P. Progressive myoclonus epilepsy with demyelinating peripheral neuropathy and preserved intellect: a novel syndrome. <span><span class="ref-journal">Arch Neurol. </span>2009;<span class="ref-vol">66</span>:898–901.</span> [<a href="/pubmed/19597094" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19597094</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.crompton.2012.474">Crompton DE, Sadleir LG, Bromhead CJ, Bahlo M, Bellows ST, Arsov T, Harty R, Lawrence KM, Dunne JW, Berkovic SF, Scheffer IE. Familial adult myoclonic epilepsy: recognition of mild phenotypes and refinement of the 2q locus. <span><span class="ref-journal">Arch Neurol. </span>2012 Apr;<span class="ref-vol">69</span>(4):474–81.</span> [<a href="/pubmed/22491192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22491192</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.dahl.1988.296">Dahl N, Erikson A, Hammarstrom-Heeroma K, Pettersson U. Tight linkage between type III Gaucher's disease (Norrbottnian type) and a MspI polymorphism within the gene for human glucocerebrosidase. <span><span class="ref-journal">Genomics. </span>1988;<span class="ref-vol">3</span>:296–8.</span> [<a href="/pubmed/2468600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2468600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.depienne.2010.2000">Depienne C, Magnin E, Bouteiller D, Stevanin G, Saint-Martin C, Vidailhet M, Apartis E, Hirsch E, LeGuern E, Labauge P, Rumbach L. Familial cortical myoclonic tremor with epilepsy: the third locus (FCMTE3) maps to 5p. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">74</span>:2000–3.</span> [<a href="/pubmed/20548044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20548044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.dibbens.2011.812">Dibbens LM, Karakis I, Bayly MA, Costello DJ, Cole AJ, Berkovic SF. Mutation of SCARB2 in a patient with progressive myoclonus epilepsy and demyelinating peripheral neuropathy. <span><span class="ref-journal">Arch Neurol. </span>2011;<span class="ref-vol">68</span>:812–3.</span> [<a href="/pubmed/21670406" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21670406</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.dibbens.2009.532">Dibbens LM, Michelucci R, Gambardella A, Andermann F, Rubboli G, Bayly MA, Joensuu T, Vears DF, Franceschetti S, Canafoglia L, Wallace R, Bassuk AG, Power DA, Tassinari CA, Andermann E, Lehesjoki AE, Berkovic SF. SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">66</span>:532–6.</span> [<a href="/pubmed/19847901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19847901</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.eskelinen.2003.137">Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. <span><span class="ref-journal">Trends Cell Biol. </span>2003;<span class="ref-vol">13</span>:137–45.</span> [<a href="/pubmed/12628346" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12628346</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.finsterer.2012.316">Finsterer J, Zarrouk Mahjoub S. Epilepsy in mitochondrial disorders. <span><span class="ref-journal">Seizure. </span>2012;<span class="ref-vol">21</span>:316–21.</span> [<a href="/pubmed/22459315" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22459315</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.fu.2014.551">Fu YJ, Aida I, Tada M, Tada M, Toyoshima Y, Takeda S, Nakajima T, Naito H, Nishizawa M, Onodera O, Kakita A, Takahashi H. Progressive myoclonus epilepsy: extraneuronal brown pigment deposition and system neurodegeneration in the brains of Japanese patients with novel SCARB2 mutations. <span><span class="ref-journal">Neuropathol Appl Neurobiol. </span>2014;<span class="ref-vol">40</span>:551–63.</span> [<a href="/pubmed/23659519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23659519</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.gamp.2003.631">Gamp AC, Tanaka Y, Lullmann-Rauch R, Wittke D, D'Hooge R, De Deyn PP, Moser T, Maier H, Hartmann D, Reiss K, Illert AL, von Figura K, Saftig P. LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. <span><span class="ref-journal">Hum Mol Genet. </span>2003;<span class="ref-vol">12</span>:631–46.</span> [<a href="/pubmed/12620969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12620969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.genton.2013.s8">Genton P, Thomas P, Kasteleijn-Nolst Trenite DG, Medina MT, Salas-Puig J. Clinical aspects of juvenile myoclonic epilepsy. <span><span class="ref-journal">Epilepsy Behav. </span>2013;<span class="ref-vol">28</span> Suppl 1:S8–14.</span> [<a href="/pubmed/23756488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23756488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.genton.2010.37">Genton P. Unverricht-Lundborg disease (EPM1). <span><span class="ref-journal">Epilepsia. </span>2010;<span class="ref-vol">51</span> Suppl 1:37–9.</span> [<a href="/pubmed/20331711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20331711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.guerrerol_pez.2012.1826">Guerrero-L&#x000f3;pez R, Garc&#x000ed;a-Ruiz PJ, Gir&#x000e1;ldez BG, Dur&#x000e1;n-Herrera C, Querol-Pascual MR, Ram&#x000ed;rez-Moreno JM, M&#x000e1;s S, Serratosa JM. A new SCARB2 mutation in a patient with progressive myoclonus ataxia without renal failure. <span><span class="ref-journal">Mov Disord. </span>2012;<span class="ref-vol">27</span>:1826–7.</span> [<a href="/pubmed/23225201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23225201</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.guerrini.2001.2459">Guerrini R, Bonanni P, Patrignani A, Brown P, Parmeggiani L, Grosse P, Brovedani P, Moro F, Aridon P, Carrozzo R, Casari G. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with complex partial and generalized seizures: A newly recognized epilepsy syndrome with linkage to chromosome 2p11.1-q12.2. <span><span class="ref-journal">Brain. </span>2001;<span class="ref-vol">124</span>:2459–75.</span> [<a href="/pubmed/11701600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11701600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.guerrini.1998.508">Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. <span><span class="ref-journal">Epilepsia. </span>1998;<span class="ref-vol">39</span>:508–12.</span> [<a href="/pubmed/9596203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9596203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.hagen.2011.575">Hagen MC, Murrell JR, Delisle MB, Andermann E, Andermann F, Guiot MC, Ghetti B. Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the Proteinase Inhibitor 12 gene. <span><span class="ref-journal">Brain Pathol. </span>2011;<span class="ref-vol">21</span>:575–82.</span> [<a href="/pmc/articles/PMC3709456/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3709456</span></a>] [<a href="/pubmed/21435071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21435071</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.harris.1999.289">Harris CM, Taylor DS, Vellodi A. Ocular motor abnormalities in Gaucher disease. <span><span class="ref-journal">Neuropediatrics. </span>1999;<span class="ref-vol">30</span>:289–93.</span> [<a href="/pubmed/10706022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10706022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.he.2014.598">He M, Tang BS, Li N, Mao X, Li J, Zhang JG, Xiao JJ, Wang J, Jiang H, Shen L, Guo JF, Xia K, Wang JL. Using a combination of whole-exome sequencing and homozygosity mapping to identify a novel mutation of SCARB2. <span><span class="ref-journal">Clin Genet. </span>2014;<span class="ref-vol">86</span>:598–600.</span> [<a href="/pubmed/24620919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24620919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.higashiyama.2013.552">Higashiyama Y, Doi H, Wakabayashi M, Tsurusaki Y, Miyake N, Saitsu H, Ohba C, Fukai R, Miyatake S, Joki H, Koyano S, Suzuki Y, Tanaka F, Kuroiwa Y, Matsumoto N. A novel SCARB2 mutation causing late-onset progressive myoclonus epilepsy. <span><span class="ref-journal">Mov Disord. </span>2013;<span class="ref-vol">28</span>:552–3.</span> [<a href="/pubmed/23325613" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23325613</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.hopfner.2011.134">Hopfner F, Schormair B, Knauf F, Berthele A, Tolle TR, Baron R, Maier C, Treede RD, Binder A, Sommer C, Maihofner C, Kunz W, Zimprich F, Heemann U, Pfeufer A, Nabauer M, Kaab S, Nowak B, Gieger C, Lichtner P, Trenkwalder C, Oexle K, Winkelmann J. Novel SCARB2 mutation in action myoclonus-renal failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features. <span><span class="ref-journal">BMC Neurol. </span>2011;<span class="ref-vol">11</span>:134.</span> [<a href="/pmc/articles/PMC3222607/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3222607</span></a>] [<a href="/pubmed/22032306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22032306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.ikeda.1990.1561">Ikeda A, Kakigi R, Funai N, Neshige R, Kuroda Y, Shibasaki H. Cortical tremor: a variant of cortical reflex myoclonus. <span><span class="ref-journal">Neurology. </span>1990;<span class="ref-vol">40</span>:1561–5.</span> [<a href="/pubmed/2215948" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2215948</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. <span><span class="ref-journal">Epilepsia. </span>2008;<span class="ref-vol">49</span>:549–56.</span> [<a href="/pubmed/18325013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18325013</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.klein.2002">Klein C. Myoclonus and myoclonus-dystonias. In: Pulst S, ed. <em>Genetics of Movement Disorders</em>. San Diego, CA: Academic Press; 2002:449-69.</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.knipper.2006.73">Knipper M, Claussen C, Ruttiger L, Zimmermann U, Lullmann-Rauch R, Eskelinen EL, Schroder J, Schwake M, Saftig P. Deafness in LIMP2-deficient mice due to early loss of the potassium channel KCNQ1/KCNE1 in marginal cells of the stria vascularis. <span><span class="ref-journal">J Physiol. </span>2006;<span class="ref-vol">576</span>:73–86.</span> [<a href="/pmc/articles/PMC1995639/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1995639</span></a>] [<a href="/pubmed/16901941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16901941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.mart_mass_.2013.1399">Mart&#x000ed;-Mass&#x000f3; JF, Bergareche A, Makarov V, Ruiz-Martinez J, Gorostidi A, L&#x000f3;pez de Munain A, Poza JJ, Striano P, Buxbaum JD, Pais&#x000e1;n-Ruiz C. The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism. <span><span class="ref-journal">J Mol Med (Berl). </span>2013;<span class="ref-vol">91</span>:1399–406.</span> [<a href="/pmc/articles/PMC3833949/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3833949</span></a>] [<a href="/pubmed/23955123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23955123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.minassian.1998.171">Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I, Gardner R, Fong CY, Carpenter S, Jardim L, Satishchandra P, Andermann E, Snead OC, Lopes-Cendes I, Tsui LC, Delgado-Escueta AV, Rouleau GA, Scherer SW. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. <span><span class="ref-journal">Nat Genet. </span>1998;<span class="ref-vol">20</span>:171–4.</span> [<a href="/pubmed/9771710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9771710</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.mink.2013.1101">Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. <span><span class="ref-journal">J Child Neurol. </span>2013;<span class="ref-vol">28</span>:1101–5.</span> [<a href="/pmc/articles/PMC3979348/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3979348</span></a>] [<a href="/pubmed/23838030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23838030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.mitchison.1998.291">Mitchison HM, Hofmann SL, Becerra CH, Munroe PB, Lake BD, Crow YJ, Stephenson JB, Williams RE, Hofman IL, Taschner PE, Martin JJ, Philippart M, Andermann E, Andermann F, Mole SE, Gardiner RM, O'Rawe AM. Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits. <span><span class="ref-journal">Hum Mol Genet. </span>1998;<span class="ref-vol">7</span>:291–7.</span> [<a href="/pubmed/9425237" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9425237</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.muona.2015.39">Muona M, Berkovic SF, Dibbens LM, Oliver KL, Maljevic S, Bayly MA, Joensuu T, Canafoglia L, Franceschetti S, Michelucci R, Markkinen S, Heron SE, Hildebrand MS, Andermann E, Andermann F, Gambardella A, Tinuper P, Licchetta L, Scheffer IE, Criscuolo C, Filla A, Ferlazzo E, Ahmad J, Ahmad A, Baykan B, Said E, Topcu M, Riguzzi P, King MD, Ozkara C, Andrade DM, Engelsen BA, Crespel A, Lindenau M, Lohmann E, Saletti V, Massano J, Privitera M, Espay AJ, Kauffmann B, Duchowny M, M&#x000f8;ller RS, Straussberg R, Afawi Z, Ben-Zeev B, Samocha KE, Daly MJ, Petrou S, Lerche H, Palotie A, Lehesjoki A. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. <span><span class="ref-journal">Nat Genet. </span>2015;<span class="ref-vol">47</span>:39–46.</span> [<a href="/pmc/articles/PMC4281260/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4281260</span></a>] [<a href="/pubmed/25401298" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25401298</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.nijssen.2003.574">Nijssen PC, Ceuterick C, van Diggelen OP, Elleder M, Martin JJ, Teepen JL, Tyynel&#x000e4; J, Roos RA. Autosomal dominant adult neuronal ceroid lipofuscinosis: a novel form of NCL with granular osmiophilic deposits without palmitoyl protein thioesterase 1 deficiency. <span><span class="ref-journal">Brain Pathol. </span>2003;<span class="ref-vol">13</span>:574–81.</span> [<a href="/pubmed/14655761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14655761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.noskov_.2011.241">Noskov&#x000e1; L, Str&#x000e1;neck&#x000fd; V, Hartmannov&#x000e1; H, P&#x00159;istoupilov&#x000e1; A, Bare&#x00161;ov&#x000e1; V, Iv&#x000e1;nek R, H&#x0016f;lkov&#x000e1; H, Jahnov&#x000e1; H, van der Zee J, Staropoli JF, Sims KB, Tyynel&#x000e4; J, Van Broeckhoven C, Nijssen PC, Mole SE, Elleder M, Kmoch S. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. <span><span class="ref-journal">Am J Hum Genet. </span>2011;<span class="ref-vol">89</span>:241–52.</span> [<a href="/pmc/articles/PMC3155175/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3155175</span></a>] [<a href="/pubmed/21820099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21820099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.perandones.2012.1200">Perandones C, Micheli FE, Pellene LA, Bayly MA, Berkovic SF, Dibbens LM. A case of severe hearing loss in action myoclonus renal failure syndrome resulting from mutation in SCARB2. <span><span class="ref-journal">Mov Disord. </span>2012;<span class="ref-vol">27</span>:1200–1.</span> [<a href="/pubmed/22767442" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22767442</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.perandones.2014">Perandones C, Pellene LA, Micheli F. Reply: A new SCARB2 mutation in a patient with progressive myoclonus ataxia without renal failure. Mov Disord. 2014.29:158-9. [<a href="/pubmed/24339182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24339182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.ramadan.2007.387">Ramadan H, Al-Din AS, Ismail A, Balen F, Varma A, Twomey A, Watts R, Jackson M, Anderson G, Green E, Mole SE. Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">68</span>:387–8.</span> [<a href="/pubmed/17261688" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17261688</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.reczek.2007.770">Reczek D, Schwake M, Schroder J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. <span><span class="ref-journal">Cell. </span>2007;<span class="ref-vol">131</span>:770–83.</span> [<a href="/pubmed/18022370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18022370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.roze.2008.1010">Roze E, Apartis E, Clot F, Dorison N, Thobois S, Guyant-Marechal L, Tranchant C, Damier P, Doummar D, Bahi-Buisson N, Andr&#x000e9;-Obadia N, Maltete D, Echaniz-Laguna A, Pereon Y, Beaugendre Y, Dupont S, De Greslan T, Jedynak CP, Ponsot G, Dussaule JC, Brice A, D&#x000fc;rr A, Vidailhet M. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">70</span>:1010–6.</span> [<a href="/pubmed/18362280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18362280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.rubboli.2011.2356">Rubboli G, Franceschetti S, Berkovic SF, Canafoglia L, Gambardella A, Dibbens LM, Riguzzi P, Campieri C, Magaudda A, Tassinari CA, Michelucci R. Clinical and neurophysiologic features of progressive myoclonus epilepsy without renal failure caused by SCARB2 mutations. <span><span class="ref-journal">Epilepsia. </span>2011;<span class="ref-vol">52</span>:2356–63.</span> [<a href="/pubmed/22050460" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22050460</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.schroen.2007.1227">Schroen B, Leenders JJ, van Erk A, Bertrand AT, van Loon M, van Leeuwen RE, Kubben N, Duisters RF, Schellings MW, Janssen BJ, Debets JJ, Schwake M, Hoydal MA, Heymans S, Saftig P, Pinto YM. Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. <span><span class="ref-journal">J Exp Med. </span>2007;<span class="ref-vol">204</span>:1227–35.</span> [<a href="/pmc/articles/PMC2118572/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2118572</span></a>] [<a href="/pubmed/17485520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17485520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.sleat.2009.1708">Sleat DE, Ding L, Wang S, Zhao C, Wang Y, Xin W, Zheng H, Moore DF, Sims KB, Lobel P. Mass spectrometry-based protein profiling to determine the cause of lysosomal storage diseases of unknown etiology. <span><span class="ref-journal">Mol Cell Proteomics. </span>2009;<span class="ref-vol">8</span>:1708–18.</span> [<a href="/pmc/articles/PMC2709195/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2709195</span></a>] [<a href="/pubmed/19383612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19383612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.smith.2013.1417">Smith KR, Dahl HH, Canafoglia L, Andermann E, Damiano J, Morbin M, Bruni AC, Giaccone G, Cossette P, Saftig P, Gr&#x000f6;tzinger J, Schwake M, Andermann F, Staropoli JF, Sims KB, Mole SE, Franceschetti S, Alexander NA, Cooper JD, Chapman HA, Carpenter S, Berkovic SF, Bahlo M. Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. <span><span class="ref-journal">Hum Mol Genet. </span>2013;<span class="ref-vol">22</span>:1417–23.</span> [<a href="/pmc/articles/PMC3596852/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3596852</span></a>] [<a href="/pubmed/23297359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23297359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.smith.2012.1102">Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF, Sims KB, Lewis J, Lin WL, Dickson DW, Dahl HH, Bahlo M, Berkovic SF. Strikingly different clinicopathological phenotypes determined by progranulin mutation dosage. <span><span class="ref-journal">Am J Hum Genet. </span>2012;<span class="ref-vol">90</span>:1102–7.</span> [<a href="/pmc/articles/PMC3370276/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3370276</span></a>] [<a href="/pubmed/22608501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22608501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.stogmann.2013.1155">Stogmann E, Reinthaler E, Eltawil S, El Etribi MA, Hemeda M, El Nahhas N, Gaber AM, Fouad A, Edris S, Benet-Pages A, Eck SH, Pataraia E, Mei D, Brice A, Lesage S, Guerrini R, Zimprich F, Strom TM, Zimprich A. Autosomal recessive cortical myoclonic tremor and epilepsy: association with a mutation in the potassium channel associated gene CNTN2. <span><span class="ref-journal">Brain. </span>2013;<span class="ref-vol">136</span>:1155–60.</span> [<a href="/pubmed/23518707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23518707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.striano.2010.669">Striano P, Robbiano A, Zara F, Striano S. Familial cortical tremor and epilepsy: a well-defined syndrome with genetic heterogeneity waiting for nosological placement in the ILAE classification. <span><span class="ref-journal">Epilepsy Behav. </span>2010;<span class="ref-vol">19</span>:669.</span> [<a href="/pubmed/20974551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20974551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.takano.1998.1060">Takano H, Cancel G, Ikeuchi T, Lorenzetti D, Mawad R, Stevanin G, Didierjean O, D&#x000fc;rr A, Oyake M, Shimohata T, Sasaki R, Koide R, Igarashi S, Hayashi S, Takiyama Y, Nishizawa M, Tanaka H, Zoghbi H, Brice A, Tsuji S. Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">63</span>:1060–6.</span> [<a href="/pmc/articles/PMC1377499/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377499</span></a>] [<a href="/pubmed/9758625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9758625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.tao.2011.138">Tao H, Manak JR, Sowers L, Mei X, Kiyonari H, Abe T, Dahdaleh NS, Yang T, Wu S, Chen S, Fox MH, Gurnett C, Montine T, Bird T, Shaffer LG, Rosenfeld JA, McConnell J, Madan-Khetarpal S, Berry-Kravis E, Griesbach H, Saneto RP, Scott MP, Antic D, Reed J, Boland R, Ehaideb SN, El-Shanti H, Mahajan VB, Ferguson PJ, Axelrod JD, Lehesjoki AE, Fritzsch B, Slusarski DC, Wemmie J, Ueno N, Bassuk AG. Mutations in prickle orthologs cause seizures in flies, mice, and humans. <span><span class="ref-journal">Am J Hum Genet. </span>2011;<span class="ref-vol">88</span>:138–49.</span> [<a href="/pmc/articles/PMC3035715/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3035715</span></a>] [<a href="/pubmed/21276947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21276947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.tsuji.1987.570">Tsuji S, Choudary PV, Martin BM, Stubblefield BK, Mayor JA, Barranger JA, Ginns EI. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. <span><span class="ref-journal">New Eng J Med. </span>1987;<span class="ref-vol">316</span>:570–5.</span> [<a href="/pubmed/2880291" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2880291</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.tsuji.2012.587">Tsuji S. Dentatorubral-pallidoluysian atrophy. <span><span class="ref-journal">Handb Clin Neurol. </span>2012;<span class="ref-vol">103</span>:587–94.</span> [<a href="/pubmed/21827919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21827919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.vadlamudi.2006.1310">Vadlamudi L, Vears DF, Hughes A, Pedagogus E, Berkovic SF. Action myoclonus-renal failure syndrome: a cause for worsening tremor in young adults. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:1310–1.</span> [<a href="/pubmed/17030781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17030781</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.van_diggelen.2001.269">van Diggelen OP, Thobois S, Tilikete C, Zabot MT, Keulemans JL, van Bunderen PA, Taschner PE, Losekoot M, Voznyi YV. Adult neuronal ceroid lipofusciosis with palmitoyl-proteinthioesterase deficiency: first adultt-onset patients of a childhood disease. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">50</span>:269–72.</span> [<a href="/pubmed/11506414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11506414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.velayati.2011.1232">Velayati A, DePaolo J, Gupta N, Choi JH, Moaven N, Westbroek W, Goker-Alpan O, Goldin E, Stubblefield BK, Kolodny E, Tayebi N, Sidransky E. A mutation in SCARB2 is a modifier in Gaucher disease. <span><span class="ref-journal">Hum Mutat. </span>2011;<span class="ref-vol">32</span>:1232–8.</span> [<a href="/pmc/articles/PMC3196787/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3196787</span></a>] [<a href="/pubmed/21796727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21796727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.xin.2010.565">Xin W, Mullen TE, Kiely R, Min J, Feng X, Cao Y, O'Malley L, Shen Y, Chu-Shore C, Mole SE, Goebel HH, Sims K. CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">74</span>:565–71.</span> [<a href="/pubmed/20157158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20157158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.yamayoshi.2012a.32">Yamayoshi S, Fujii K, Koike S. Scavenger receptor b2 as a receptor for hand, foot, and mouth disease and severe neurological diseases. <span><span class="ref-journal">Front Microbiol. </span>2012a;<span class="ref-vol">3</span>:32.</span> [<a href="/pmc/articles/PMC3277273/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3277273</span></a>] [<a href="/pubmed/22363322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22363322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.yamayoshi.2012b.5686">Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. <span><span class="ref-journal">J Virol. </span>2012b;<span class="ref-vol">86</span>:5686–96.</span> [<a href="/pmc/articles/PMC3347270/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3347270</span></a>] [<a href="/pubmed/22438546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22438546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.yamayoshi.2013.3335">Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. <span><span class="ref-journal">J Virol. </span>2013;<span class="ref-vol">87</span>:3335–47.</span> [<a href="/pmc/articles/PMC3592140/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3592140</span></a>] [<a href="/pubmed/23302872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23302872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.yamayoshi.2009.798">Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. <span><span class="ref-journal">Nat Med. </span>2009;<span class="ref-vol">15</span>:798–801.</span> [<a href="/pubmed/19543282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19543282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.zeigler.2014.210">Zeigler M, Meiner V, Newman JP, Steiner-Birmanns B, Bargal R, Sury V, Mengistu G, Kakhlon O, Leykin I, Argov Z, Abramsky O, Lossos A. A novel SCARB2 mutation in progressive myoclonus epilepsy indicated by reduced beta-glucocerebrosidase activity. <span><span class="ref-journal">J Neurol Sci. </span>2014;<span class="ref-vol">339</span>:210–3.</span> [<a href="/pubmed/24485911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24485911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.zifkin.2005.147">Zifkin B, Andermann E, Andermann F. Mechanisms, genetics, and pathogenesis of juvenile myoclonic epilepsy. <span><span class="ref-journal">Curr Opin Neurol. </span>2005;<span class="ref-vol">18</span>:147–53.</span> [<a href="/pubmed/15791145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15791145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="amrf.REF.zimprich.2001.66">Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidtmann K, Kern P, Winkelmann J, M&#x000fc;ller-Myhsok B, Riedel L, Bauer M, M&#x000fc;ller T, Castro M, Meitinger T, Strom TM, Gasser T. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:66–9.</span> [<a href="/pubmed/11528394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11528394</span></a>]</div></li></ul></div></div><div id="amrf.Chapter_Notes"><h2 id="_amrf_Chapter_Notes_">Chapter Notes</h2><div id="amrf.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>17 December 2015 (me) Review posted live</div></li><li class="half_rhythm"><div>25 February 2014 (da) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK333437</span><span class="label">PMID: <a href="/pubmed/26677510" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">26677510</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/npab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/aip/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK333437&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK333437/?report=reader">PubReader</a></li><li><a href="/books/NBK333437/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK333437" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK333437" style="display:none" title="Cite this Page"><div class="bk_tt">Amrom D, Andermann F, Andermann E. Action Myoclonus – Renal Failure Syndrome. 2015 Dec 17. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK333437/pdf/Bookshelf_NBK333437.pdf">PDF version of this page</a> (510K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#amrf.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#amrf.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#amrf.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#amrf.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#amrf.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#amrf.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#amrf.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#amrf.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#amrf.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#amrf.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#amrf.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=950[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SCARB2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4185534" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4185534" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4185534" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4185534" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25719194" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">TBC1D24</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">TBC1D24</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mucha BE, Hennekam RCM, Sisodiya S, Campeau PM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29595935" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ASAH1</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ASAH1</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dyment DA, Bennett SAL, Medin JA, Levade T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301774" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PRICKLE1</i>-Related Progressive Myoclonus Epilepsy with Ataxia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PRICKLE1</i>-Related Progressive Myoclonus Epilepsy with Ataxia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fox MH, Bassuk AG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301791" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">POLG</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">POLG</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cohen BH, Chinnery PF, Copeland WC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301563" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Progressive Myoclonus Epilepsy, Lafora Type</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Progressive Myoclonus Epilepsy, Lafora Type<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Jansen AC, Andermann E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=26677510" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=26677510" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041b0475f66d18aabc4f37">Action Myoclonus – Renal Failure Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Action Myoclonus – Renal Failure Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:29:24-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C224EE04171F100000000019F008E&amp;ncbi_session=CE8C224EE041B031_0415SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK333437%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK333437&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK333437/&amp;ncbi_pagename=Action Myoclonus – Renal Failure Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C224EE041B031_0415SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>